

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: INHIBITION OF GENE EXPRESSION USING
POLYNUCLEOTIDE ANALOGUES

APPLICANT: STEPHEN C. EKKER, AIDAS NASEVICIUS, HYON KIM
AND SAULIUS SUMANAS

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL734684714US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

July 30, 2001
Date of Deposit


Signature

Vince Defante
Typed or Printed Name of Person Signing Certificate

INHIBITION OF GENE EXPRESSION USING POLYNUCLEOTIDE ANALOGUES

5

Cross Reference To Related Applications

This application claims priority from U.S. Provisional Application Serial No. 60/221 722, filed July 31, 2000; U.S. Provisional Application Serial No. 60/252 864, filed November 22, 2000; and U.S. Provisional Application Serial No. 60/284 974, filed April 19, 2001.

10

Statement as to Federally Sponsored Research

Funding for the work described herein was provided by the federal government, which may have certain rights in the invention.

15

BACKGROUND

1. Technical Field

The invention relates to methods and materials involved in the determination of the function of a nucleic acid based on its sequence.

20

2. Background Information

The ability of the various genome projects to acquire gene sequence data has far outpaced the ability to ascribe biological functions to these new genes. This dilemma has led to the concept of "functional genomics" which can be defined as the attempt to match biological function with gene sequence on a genome scale. Since many biological processes are well conserved in evolution, model organisms for which rapid genetic tools have been developed can be used as model systems to identify human genes. For example, genes with specific biological roles are identified first in the model organism, and then genome databases are used to identify human homologues.

25

30

A useful model system for the study of vertebrate biology is the zebrafish *Danio rerio*. Aspects of the zebrafish developmental process that render the zebrafish useful as

a model system include rapid development of the organ systems, transparent embryos, embryos that develop outside the womb, and availability of a large number of embryos. Furthermore, the sequence of the zebrafish genome is expected to be completed by the end of 2002. Assignment of function based on sequence information would be greatly facilitated by the development of a rapid, targeted, knockdown technology in this model vertebrate.

Recently, a number of strategies have been developed for selectively repressing the expression of specific genes. These methods are based on inducing degradation of cognate mRNAs by introduction of double-stranded RNA into cells or addition of single stranded antisense RNAs that trigger mRNA degradation by RNase H. Although these methods have been used in *D. melanogaster* and *C. elegans*, they have been unsuccessful in fish due to toxicity, nonspecific effects, or the inability to achieve uniform distribution for gene repression.

SUMMARY

The invention provides methods and materials for determining the function of a nucleic acid of known sequence. More specifically, the invention provides methods and materials for determining the function of, or a phenotype associated with, a selected nucleic acid of known sequence by specifically reducing expression from the selected nucleic acid in a teleost. The invention provides sequence specific polynucleotide analogues that can be used to specifically reduce expression from selected nucleic acids as well as methods of using sequence-specific polynucleotide analogues to reduce expression from selected nucleic acids. The function of, or phenotype associated with, a selected nucleic acid can be determined by examining morphological or other phenotypic alterations associated with the presence of a sequence-specific polynucleotide analogue in an organism.

The invention provides a teleost embryo containing a polynucleotide analogue in an amount effective to reduce expression from a selected nucleic acid in the embryo. The embryo is of a teleost species that undergoes meroblastic cleavage. The embryo can be, for example, a zebrafish embryo, a puffer fish embryo, a medaka embryo, or a stickleback embryo.

The polynucleotide analogue can be used to reduce expression from a selected nucleic acid that is an mRNA. The analogue can be complementary to a region of the mRNA that includes (1) the 5' untranslated region of the mRNA, (2) part of or the entire AUG start codon of the mRNA, (3) the coding region of the mRNA, or (4) various combinations of the above. The length of the analogue can be, for example, 9 to 90 bases in length, 15 to 50 bases in length, or 20 to 30 bases in length. The analogue can be a morpholino-modified polynucleotide, a 3'-5' phosphoroamidate, a peptide nucleic acid, or a polynucleotide containing a ribose moiety that has a 2' O-methyl group. The analogue can have at least 15 % non-complementary nucleotides compared to the corresponding nucleotides in the selected nucleic acid. The analogue can be complementary to a nucleic acid in the embryo that has a homologue or orthologue in another species. The analogue can be used to reduce expression from the selected nucleic acid through larval or post-hatching stages of development.

The invention also provides for an embryo containing an exogenous rescue mRNA that encodes a polypeptide whose expression is reduced by the polynucleotide analogue. The rescue mRNA is present in an amount sufficient for expression of the polypeptide at a level comparable to that in embryos free of the analogue.

The invention also provides for an embryo that has at least one additional polynucleotide analogue that is complementary to a different region of the same selected nucleic acid. Both analogues are present in amounts effective to reduce expression from the selected nucleic acid.

The invention also provides for an embryo that has at least one additional polynucleotide analogue that is complementary to at least one other nucleic acid that is different from the first. All analogues are present in amounts effective to reduce expression from each of the different nucleic acids.

In another embodiment, the invention provides a method for producing a teleost embryo containing a polynucleotide analogue. The embryo can be a teleost embryo that undergoes meroblastic cleavage. The analogue is present in an amount effective to reduce expression from a selected nucleic acid in the embryo. The method involves contacting the embryo, or an egg giving rise to the embryo, with the polynucleotide analogue. For example, the embryo or egg giving rise to the embryo can be injected with

the analogue or the analogue can be added to the surface of the embryo or egg giving rise to the embryo. The embryo or egg giving rise to the embryo can be a zebrafish embryo or egg giving rise to the zebrafish embryo, a puffer fish embryo or egg giving rise to the puffer fish embryo, a medaka embryo or egg giving rise to the medaka embryo, or a stickleback embryo or egg giving rise to the stickleback embryo.

In another embodiment, the invention also provides a composition comprising a morpholino-modified polynucleotide that is complementary to a selected nucleic acid and a buffer having a pH similar to the physiological pH within a teleost egg or embryo. The buffer can be isotonic to the teleost egg or embryo. The buffer can be Danieau buffer.

The teleost egg or embryo can be that of a species that undergoes meroblastic cleavage. The teleost egg or embryo can be a zebrafish egg or embryo, a puffer fish egg or embryo, a medaka egg or embryo, or a stickleback egg or embryo. In addition, the composition also can contain a rescue mRNA that encodes a polypeptide whose expression is reduced by the morpholino-modified analogue. The composition also can contain at least one additional polynucleotide analogue that is complementary to different regions of the selected nucleic acid.

In another embodiment, the invention provides method for determining a phenotype associated with a selected nucleic acid in a teleost embryo or egg giving rise to the embryo. The embryo or egg is that of teleost species that undergoes meroblastic cleavage. The method involves contacting the teleost embryo or egg giving rise to the embryo with a morpholino-modified polynucleotide analogue that targets the selected nucleic acid and then detecting an altered phenotype in the teleost embryo or egg, or embryo developing from said egg. The altered phenotype is one that is associated with reduced expression or altered function of said selected nucleic acid. The selected nucleic acid can be a maternal or zygotic nucleic acid and the altered phenotype can be observed from fertilization, through organogenesis, to the completion of embryogenesis.

The invention also provides a method for determining a phenotype associated with a selected nucleic acid in a teleost embryo or egg giving rise to the embryo. The embryo or egg is that of teleost species that undergoes meroblastic cleavage. The method involves contacting the teleost embryo or egg giving rise to the embryo with a morpholino-modified polynucleotide and a rescue mRNA and then detecting an altered

phenotype in the teleost embryo or egg, or embryo developing from said egg. The morpholino-modified polynucleotide is present in an amount effective to reduce expression from the nucleic acid. The rescue mRNA encodes a polypeptide whose expression is reduced by the analogue and is present in an amount sufficient for expression of the polypeptide at a level comparable to that of a teleost embryo, or egg giving rise to said embryo, that is free of the analogue.

In another embodiment, the invention provides a method for determining if a phenotype mediated by a polynucleotide analogue in a teleost organism is sequence-specific. The method involves contacting a first teleost embryo or teleost egg with the polynucleotide analogue and assessing the phenotype of the first teleost embryo or egg, or a teleost embryo developing from the egg, subsequent to contacting with the polynucleotide analogue. A second teleost embryo or teleost egg is contacted with (i) the polynucleotide analogue and (ii) a rescue mRNA molecule and the phenotype of the second teleost embryo or egg, or a teleost embryo developing from the egg, is subsequently assessed. The method then involves comparing the phenotype of the first embryo or egg to the phenotype of the second embryo or egg. The analogue is sequence-specific if the phenotype of the first embryo or egg is not found in the second embryo or egg.

In another embodiment, the invention provides a method of determining if first and second polypeptides are genetic interactors. The method involves contacting a first teleost embryo or teleost egg with a first polynucleotide analogue that targets a nucleic acid encoding a first polypeptide, and assessing the phenotype of the resulting teleost embryo or egg, or a teleost embryo developing from the egg. The method also involves contacting a second teleost embryo or egg giving rise to the embryo with a second polynucleotide analogue that targets a nucleic acid encoding the second polypeptide, and assessing the phenotype of the resulting teleost embryo or egg, or a teleost embryo developing from the egg. The method also involves contacting a third teleost embryo or egg giving rise to the embryo with the first and second polynucleotide analogues, and assessing the phenotype of the resulting teleost embryo or egg, or a teleost embryo developing from the egg. The phenotypes of the resulting first, second, and third teleost embryos or eggs, or teleost embryos developing from such eggs, are compared. The two

polypeptides are genetic interactors if the phenotype observed in the third embryo or egg is different from the sum of the individual phenotypes observed in the first and second embryos or eggs. The phenotype observed when both polynucleotide analogues are used can be more or less extensive than the sum of the individual phenotypes observed when one of the two analogues is used.

In another embodiment, the invention provides a kit comprising a collection of different morpholino-modified polynucleotides. The different morpholino-modified polynucleotides are effective to reduce expression from different nucleic acids that are involved in a common metabolic process.

In another embodiment, the invention provides a collection of morphants, each morphant generated by a different morpholino-modified polynucleotide selected from a collection of morpholino-modified polynucleotides effective to reduce expression from different nucleic acids that are involved in a common metabolic process.

In another embodiment, the invention provides a teleost morphant defective in development of a differentiated tissue. The differentiated tissue can be pancreas, vasculature tissue, blood, eye, the central neural system, muscle, the backbone, the head, a limb, or a pigment cell.

In another embodiment, the invention provides a teleost morphant that has a phenotype characteristic of a disease condition. The disease condition can be, for example, porphyria or cyclopia.

In another embodiment, the invention provides a method of identifying a nucleic acid associated with a disease condition. The method involves generating a teleost morphant having a morphant phenotype that corresponds to a phenotype characteristic of the disease condition, and identifying the nucleic acid target of the morpholino-modified polynucleotide in the teleost morphant. The nucleic acid target of the morpholino-modified polynucleotide is a nucleic acid associated with the disease condition.

In another embodiment, the invention provides a method for assessing the effect of a drug on a morphant. The method involves contacting the morphant with the drug and assessing the phenotype of the morphant subsequent to contact with the drug. The phenotype of the morphant can be unaltered subsequent to contact with the drug or replaced by a less severe phenotype subsequent to contact with the drug. The phenotype

of the morphant, subsequent to contact with said drug, can be correlated with a change in the activity of a biomarker.

In another embodiment, the invention provides a method of reducing expression from a selected nucleic acid in an animal. The method involves administering at least two polynucleotide analogues to the animal. The analogues are complementary to different regions of the selected nucleic acid. The polynucleotide analogues can act synergistically to reduce expression from the selected nucleic acid. Such expression can be reduced by a synergy factor of 3, 5, or 10. The polynucleotide analogues can be morpholino-modified polynucleotides.

In another embodiment, the invention provides a composition comprising at least two different morpholino-modified polynucleotides and a pharmaceutically acceptable carrier. The morpholino-modified polynucleotides can target the same selected nucleic acid and can be complementary to non-overlapping regions of the selected nucleic acid. The non-overlapping regions can be separated by more than 1 000 nucleotides.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

DESCRIPTION OF DRAWINGS

Figure 1 is a GFP fluorescence inhibition graph demonstrating sequence-specific and dose-dependent inhibition of GFP expression.

Figure 2 is a graph demonstrating that two chordin-MO phenotypes, weak and strong, were achieved with increasing doses of chordin-MO injected.

Figure 3 is a bar graph demonstrating that the chordin-MO phenotype was partially rescued by *Xenopus* chordin mRNA injection, thereby illustrating specificity of chordin-MO targeting.

Figure 4 is a bar graph demonstrating dose-dependent reduction in the frequency of the *oep* phenotype in response to *oep* mRNA injections.

Figure 5 is a bar graph comparing the frequencies of *ntl*, *oep*, and *ntl* and *oep* phenotypes observed in embryos injected with *ntl*-MO, *oep*-MO, or both MOs.

Figure 6 is a bar graph comparing the frequencies of cyclopia, u-somites, and reduced fins in embryos injected with a control-MO and *twhh*-MO, a control-MO and *shh*-MO, or both *twhh*- and *shh*-MOs.

Figures 7A and 7B are bar graphs demonstrating synergy between two *shh*-MOs.

Figure 8 is a bar graph demonstrating synergy between two VEGF-MOs.

Figure 9 is a bar graph demonstrating synergy between two *zfp*-MOs.

Figure 10 is a bar graph demonstrating the synergistic effects of *zfp1*- and chordin-MO on blood island expansion.

DETAILED DESCRIPTION

The invention provides methods and materials for determining the function of a nucleic acid of known sequence. More specifically, the invention provides methods and materials for determining the function of, or a phenotype associated with, a selected nucleic acid of known sequence by specifically reducing expression from the selected nucleic acid in a teleost. The invention provides sequence specific polynucleotide analogues that can be used to specifically reduce expression from selected nucleic acids as well as methods of using sequence-specific polynucleotide analogues to reduce expression from selected nucleic acids. For example, the invention provides morpholino-modified polynucleotides and methods of using morpholino-modified polynucleotides for reducing expression of selected nucleic acids whose sequences are known. Reduction in expression is reflected in the level of specific RNA or polypeptide produced as well as in morphological or other phenotypic changes. The function of, or phenotype associated with, a selected nucleic acid can be determined by examining morphological or other phenotypic alterations associated with the presence of a sequence-specific polynucleotide

analogue in an organism.

1. Polynucleotide and polynucleotide analogues

Polynucleotides are linear polymers consisting of monomeric subunits called nucleotides. A nucleotide has three components: a phosphate group, an organic base, and a five-carbon sugar that links the phosphate group and the organic base. The nucleotide subunits of a polynucleotide are linked by phosphodiester bonds, i.e. the five-carbon sugar of one nucleotide forms an ester bond with the phosphate of an adjacent nucleotide. The resulting sugar-phosphates form the backbone of a polynucleotide, while the organic bases determine the sequence of the polynucleotide and allow for interaction with a second polynucleotide. When the sequence of the bases of one polynucleotide is complementary to the sequence of the bases of a second polynucleotide, the two polynucleotides can anneal to form a duplex held together by hydrogen bonds and hydrophobic interactions. Two polynucleotides are said to have complementary sequences if the bases in one polynucleotide are able to pair, through hydrogen bonding, with the bases in the second polynucleotide according to known Watson-Crick type base pairing rules, (see DNA in Molecular Cell Biology, Darnell *et al.* (1990) Scientific American Books. 2nd Edition, pages 68-74). The strength of the interaction between the two polynucleotides is determined by the degree of complementarity. For example, the strength of interaction between two polynucleotides is greatest if the base sequences are 100 % complementary. Duplexes formed between two polynucleotides with 4 %, 8 %, 16 %, 25 %, or more than 25 % mismatch bases are successively less strong and will separate at successively lower temperatures. As used herein, the term “polynucleotide” refers to a DNA or an RNA polymer having at least three nucleotides.

Polynucleotide analogues are chemically modified polynucleotides. Typically, polynucleotide analogues are formed by replacing all or portions of the five-carbon sugar-phosphate backbone of a polynucleotide with alternative functional groups in such a way that base pairing with a selected nucleic acid is maintained. As used herein, the term “selected nucleic acid” refers to a DNA or an RNA having a region that is complementary to the polynucleotide analogue. The region of the selected nucleic acid that is complementary to the polynucleotide analogue can be 100 % complementary or

less than 100 % complementary to the entire polynucleotide analogue sequence, as long as the polynucleotide analogue can anneal and form a stable duplex with the selected nucleic acid under physiological conditions. For example, a polynucleotide sequence of 25 nucleotides can have as many as three non-complementary bases distributed throughout the polynucleotide and still anneal with the selected nucleic acid.

Some examples of polynucleotide analogues include: analogues in which the bases are linked by a polyvinyl backbone (Pitha *et al.* (1970) *Biochem Biophys Acta* 204:39 and Pitha *et al.* (1970) *Biopolymers* 9: 965); peptide nucleic acids (PNAs) in which the bases are linked by amide bonds formed by pseudopeptide 2- aminoethyl-glycine groups; analogues in which the nucleoside subunits (i.e. base and sugar) are linked by methylphosphonate groups (Miller *et al.* (1979) *Biochem* 18: 5134; Miller *et al.* (1980) *J Biol Chem* 255: 6959); analogues in which the phosphate residues linking nucleoside subunits are replaced by phosphoroamidate groups (Froehler *et al.* (1988) *Nucleic Acids Res* 156: 4831); phosphorothioated DNAs, analogues containing sugar moieties that have 2' O-methyl groups (Cook (1998) CHAPTER 2: Antisense Medicinal Chemistry in The Medicinal Chemistry of Oligonucleotides. Springer, New York. pages 51-101); and morpholino-modified analogues, analogues in which the bases are linked by a morpholino-phosphorodiamidate backbone (U.S. Patent Nos. 5,142,047 and 5,185,444). Polynucleotide analogues can be obtained commercially, produced using commercially available monomeric subunits, or synthesized using known methods. (See Braasch and Corey (2001) *Chemistry and Biology*, pages 1-7.)

Useful polynucleotide analogues are those that (1) can form duplexes with selected cellular nucleic acids in a sequence specific manner, (2) form duplexes that are relatively insensitive to ionic concentration or relatively resistant to cellular strand-separating mechanisms, (3) have low nuclease sensitivity, and (4) have low cellular toxicity and non-specific effects. Useful polynucleotide analogues typically are specific, can distribute uniformly throughout most or all cells of an organism, are functional in many or all cell types, are efficient at reducing expression from different nucleic acids and have little or no non-specific effects. Furthermore, the technique for use is straightforward to perform and reproducible.

Typically, useful polynucleotide analogues are single stranded, and can be various lengths such as 8 to more than 112 bases in length. Polynucleotide analogues can be 12 to 72 bases in length. For example, polynucleotide analogues can be 15 to 45 bases in length. Ideally, polynucleotide analogues are 18-30 bases in length.

5 A useful polynucleotide analogue can be complementary to a sense or an antisense nucleic acid. When complementary to a sense nucleic acid, the polynucleotide analogue is said to be antisense. When complementary to an antisense nucleic acid, the analogue is said to be sense. The nucleic acid can be RNA (e.g. a pre-mRNA or an mRNA) or DNA. For example, a useful polynucleotide analogue can be antisense to a
10 pre-mRNA or an mRNA molecule or sense to the DNA molecule from which an mRNA is transcribed.

A useful polynucleotide analogue can be complementary to the non-coding region of a nucleic acid. A non-coding region, for example, can be a region upstream of a transcriptional start point or a region downstream of a transcriptional end-point in a DNA
15 molecule. A non-coding region also can be a region upstream of the translational start codon or downstream of the stop codon in a pre-mRNA or an mRNA molecule. A non-coding region also can be the intronic sequences within a pre-mRNA (see Ekker & Larson (2001) *Genesis* 30:89-93). Furthermore, a useful polynucleotide analogue can be complementary to the coding region of a pre-mRNA molecule or an mRNA molecule, or
20 the region corresponding to the coding region on the antisense DNA strand. As used herein, the term "coding sequence" refers to the region of DNA or RNA that encodes an RNA molecule or a polypeptide having a cellular function. A useful polynucleotide analogue also can be complementary to both coding and non-coding regions of a selected nucleic acid. A polynucleotide analogue that is complementary to both coding and non-
25 coding regions of a selected nucleic acid, for example, is one that is complementary to a region that includes a portion of the 5' untranslated region leading up to the start codon, the start codon, and coding sequences immediately following the start codon of a selected mRNA. A polynucleotide analogue that is complementary to both coding and non-coding regions of a selected nucleic acid also includes one that is complementary an
30 intron/exon junction of a selected pre-mRNA molecule (see Ekker & Larson (2001) *Genesis* 30:89-93).

2. Reduction of expression

A polynucleotide analogue can be used to reduce expression from a selected nucleic acid of known sequence. As used herein, “reduction” or “reduce” with respect to expression from a nucleic acid refers to a decrease in expression, or to decrease expression, in an amount that can be detected by assessing changes in RNA level, protein level, and phenotype. For example, reduction can refer to a 5 %, 10 %, 25 %, 50 %, 75 %, or more than 75 % decrease in expression. A reduction in expression also includes complete inhibition of expression, whereby greater than 95 % reduction of expression from a nucleic acid is achieved.

As used herein, the term “expression,” with respect to expression of a gene or expression from a nucleic acid, refers to production of a functional RNA molecule from a DNA molecule as well as production of a functional polypeptide from an mRNA molecule. Expression from a selected nucleic acid can be examined using standard methods known in the art. For example, RNA levels can be determined by Northern hybridization and *in situ* hybridization using the appropriate nucleic acid hybridization probes, while polypeptide levels can be determined by antibody staining and western hybridization. Development of organs, differentiated tissues, and other cellular structures that are affected by reduction in expression of selected nucleic acids can be assessed using various methods. For example, vasculature can be visualized with FITC-dextran injections; cartilage can be visualized using Alcian Blue staining; and muscles can be visualized using fluorescent-phalloidin staining. Alternatively, the expression of tissue-specific genes can be used to assess development of organs, differentiated tissues, and particular cellular structures. For example, expression of a thymus specific marker such as Rag-1 can be used to assess thymus development; and expression of pancreas-specific markers such as Fspndin and islet-1 can be used to assess pancreas development. (For standard methodologies, see H. W. Detrich III, M. Westerfield, and L. I. Zon, Methods in Cell Biology Vol. 59: The Zebrafish Biology, Academic Press. San Diego)

Expression from a nucleic acid can be reduced by interfering with (1) any process necessary for RNA transcription, (2) RNA processing, (3) RNA transport across the

nuclear membrane, (4) any process necessary for RNA translation, or (5) RNA degradation.

Expression from a nucleic acid such as a DNA molecule can be reduced by interfering with processes necessary for formation of a functional RNA molecule or transport of the RNA into the cytoplasm. Processes necessary for formation of a functional RNA molecule include, for example, RNA polymerase binding to promoter regions, binding of transcriptional activator to its recognition sequence, and transcription. A polynucleotide analogue that anneals to DNA and interferes with processes necessary for formation of a functional RNA molecule generally, though not necessarily, has a sequence that is complementary to the antisense DNA strand from which mRNA is transcribed. Such polynucleotide analogues are referred to as "antigene" molecules.

Expression from a nucleic acid such as an RNA molecule can be reduced by interfering with any process necessary for formation of a functional RNA molecule or proper translation of an mRNA molecule into a functional polypeptide. Expression from an RNA molecule, for example, can be reduced by interfering with RNA processing, ribosome binding to the ribosome-binding site of mRNAs, interfering with initiation of translation, interfering with the translation process, or interfering with proper termination of translation (see Ekker and Larson (2001) *Genesis* 30:89-93 and Nasevicius & Ekker (2001) *Curr Opin in Mol Therapeutics* 3:224). A polynucleotide analogue that anneals to a region of an mRNA molecule and interferes with translation has a sequence that is complementary to that region of the mRNA molecule and is referred to as an antisense molecule. Antisense molecules, for example, can bind and sterically inhibit scanning of the mRNA by the 40s ribosomal subunit. Antisense molecules also can reduce expression by inducing the cellular nuclease system that degrades cognate mRNAs. In the RNaseH dependent mechanism, the double stranded mRNA/antisense RNA that is formed is degraded by RNaseH.

Reduction of expression from a selected nucleic acid can be achieved using one polynucleotide analogue. Reduction of expression from a selected nucleic acid also can be achieved using two or more polynucleotide analogues that are complementary to different regions of the same selected nucleic acid. When two or more polynucleotide analogues are used to reduce expression from a selected nucleic acid, the polynucleotide

analogues can be complementary to non-overlapping regions or to overlapping regions of the selected nucleic acid. When non-overlapping, polynucleotide analogues can be complementary to regions of the selected nucleic acid that are 0, 1, 2, 5, 10, 25, 50, 100, 500, 1000, or more than 1000 nucleotides apart.

When two or more polynucleotide analogues are used to reduce expression from a selected nucleic acid, the two or more polynucleotide analogues can have an additive or synergistic effect on the phenotype of the organism. A phenotype that results from introduction of polynucleotide analogues into a selected organism is herein referred to as a phenotype mediated by the polynucleotide analogues. The effect of two or more analogues can be described as additive or synergistic based, for example, on the penetrance frequency of a phenotype mediated by the analogues. The penetrance frequency used to determine whether the effect of two or more analogues is additive or synergistic is the frequency determined for a 1X dose of each polynucleotide analogue used. As used herein, penetrance frequency is the percent of organisms exhibiting a particular phenotype when contacted with a particular analogue. For example, if 100 organisms are contacted with analogue-1 and 80 of these exhibit phenotype-1, then the penetrance frequency is 80 %. A 1X dose of an analogue can be any amount needed to achieve a penetrance frequency of less than 50 %. To determine a 1X dose for an analogue, a dose response curve is generated for each analogue of interest. From the dose response curve, any amount of an analogue that results in a penetrance frequency less than 50 % and with minimal toxic effects can be used as the 1X dose. Two analogues are considered to have an additive effect if the penetrance frequency, obtained when both analogues are used, each at 1X dose, is equal to the sum of the penetrance frequencies of individual analogues at 1X doses. For example, two analogues are considered to have an additive effect if the penetrance frequencies are (1) 10 % for a 1X dose of analogue-1, (2) 20 % for a 1X dose of analogue-2, and (3) 30 % for a 1X dose of analogue-1 and a 1X dose of analogue-2 when used together. In contrast, two analogues are considered to have a synergistic effect if the penetrance frequency, obtained when both analogues are used, each at 1X dose, is greater than the sum of the penetrance frequencies of individual analogues at 1X doses. For example, two analogues are considered to have a synergistic effect if the penetrance frequencies are (1) 10 % for a 1X

dose of analogue-1, (2) 20 % for a 1X dose of analogue-2, and (3) 90 % for a 1X dose of analogue-1 and a 1X dose of analogue-2 when used together.

The effect of two or more analogues also can be described as, without limitation, additive or synergistic based on the severity of the phenotype mediated by the analogues compared to “the sum of the individual phenotypes” mediated by each of the analogue used. A phenotype that is “the sum of individual phenotypes” is one that results from an additive effect of each analogue. Two or more analogues are considered to have a synergistic effect if the phenotype mediated by the analogues is more severe than “the sum of the individual phenotypes.” For example, two analogues are considered to have a synergistic effect if (1) 100 % of the organisms contacted with analogue-1 exhibit a 10 % reduction in blood vessel formation, (2) 100 % of the organisms contacted with analogue-2 exhibit a 20 % reduction in blood vessel formation, and (3) 100 % of organisms contacted with analogue-1 and analogue-2 exhibit a 90 % reduction in blood vessel formation. In this example, the percent of reduction in blood vessel formation is the severity of the phenotype mediated by the polynucleotide analogues. In contrast, two analogues are considered to have an additive effect on the phenotype of an organism if the phenotype mediated by the analogues is not more severe than “the sum of the individual phenotypes.” For example, two analogues are considered to have a synergistic effect if (1) 100 % of the organisms contacted with analogue-1 exhibit a 10 % reduction in blood vessel formation, (2) 100 % of the organisms contacted with analogue-2 exhibit a 20 % reduction in blood vessel formation, and (3) 100 % of organisms contacted with analogue-1 and analogue-2 exhibit a 30 % reduction in blood vessel formation.

Phenotype severity can, in some instances, be measured by the extent of reduction in expression from the nucleic acid targeted by the analogues. The amount of reduction in expression can be quantitated by standard methodologies and then compared to determine whether two or more analogues have an additive or synergistic effect on reduction of expression.

A useful measure of the synergy of two analogues is the synergy factor. As used herein, the term “synergy factor” is defined as the penetrance frequency, or the severity of the phenotype, observed for two or more analogues divided by the expected additive penetrance frequency or “sum of the individual phenotypes,” respectively. The synergy

factor can be determined by comparing the actual penetrance frequency obtained when both analogues are used (each at 1X dose) with the penetrance frequency expected of an additive effect. For example, the synergy factor is 3 (90 %/30 %) if the penetrance frequencies are (1) 10 % for a 1X dose of analogue-1, (2) 20 % for a 1X dose of analogue-2, and (3) 90 % for a 1X dose of analogue-1 and a 1X dose of analogue-2 when used together. The synergy factor also can be determined by comparing the severity of the phenotype observed with “the sum of the individual phenotypes” when two or more analogues are used. For example, the synergy factor also is 3 (90 %/30 %) if (1) 10 % reduction in blood vessel formation is observed in 100 % of the organisms contacted with analogue-1, (2) 20 % reduction in blood vessel formation is observed in 100 % of the organisms contacted with analogue-2, and (3) 90 % reduction in blood vessel formation is observed in 100 % of organisms contacted with analogue-1 and analogue-2 together. A synergy factor can be determined for two or more polynucleotide analogues. For example, a synergy factor can be determined for two, three, or more than three analogues. A synergy factor can be any value greater than 0. For example, a synergy factor can be 0.2, 0.4, 0.8, 1.5, 2, 4, 6, 8, 10, 15, 20, or more than 20. A synergistic effect is indicated when the synergy factor for a particular group of analogues has a value greater than 1, for example, 1.2, 1.5, 1.8, 2.1, 5, 10, 20, or more than 20. A synergy factor of 1 represents an additive effect. Synergy factors between 0 and 1 indicate an interference effect.

Polynucleotide analogues also can be used to reduce expression from two or more different selected nucleic acids in an organism. For example, multiple polynucleotide analogues, i.e. at least two, having sequences complementary to multiple selected nucleic acids can be used to reduce expression from the selected nucleic acids. When two or more polynucleotide analogues are used to reduce expression from two or more nucleic acids, reduction in expression of the various nucleic acids can result in phenotypes of two classes. The first class is representative of “the sum of the individual phenotypes” mediated by each of the analogues used, while the second class consists of those phenotypes that do not fall into the first class. A phenotype that is “the sum of individual phenotypes” is one that results from an additive effect of each analogue. The additive effect of multiple polynucleotide analogues is as described for multiple polynucleotide analogues that target one selected nucleic acid. An organism that has been contacted

with two or more analogues also is described as having a phenotype that is “the sum of individual phenotypes” if the individual phenotype mediated by each analogue is distinct and present in that organism. Alternatively, organisms that have been contacted with two or more analogues can exhibit phenotypes that are not considered “the sum of individual phenotypes.” These organisms exhibit phenotypes that are more or less extensive than, or distinctly different from, a phenotype that is “the sum of individual phenotypes.” Typically, phenotypes that are not “the sum of individual phenotypes” represent synergistic or interference effects of multiple analogues.

To be considered additive, synergistic, interference, one that represents “the sum of other phenotypes,” or one that is distinctly different from a phenotype that is the “sum of individual phenotypes,” a phenotype mediated by a polynucleotide analogue must be sequence-specific, i.e., the phenotype must result from sequence-specific reduction of expression from a selected nucleic acid.

3. Determination of sequence-specific reduction of expression

A phenotype mediated by a polynucleotide analogue is said to be “sequence-specific” if the phenotype is primarily or exclusively associated with, or results from, reduction of expression from the selected nucleic acid. To determine if a phenotype mediated by a polynucleotide analogue is sequence-specific, a second polynucleotide analogue of unrelated sequence that targets the same nucleic acid can be used. Alternatively, a control polynucleotide analogue that does not target the same nucleic acid or a rescue mRNA that compensates for the reduction in expression from the selected nucleic acid can be used.

To show that a phenotype mediated by a first polynucleotide analogue is sequence-specific, a second polynucleotide analogue that also targets the same selected nucleic acid is introduced into a model organism. A phenotype mediated by the second polynucleotide analogue that is the same as the phenotype mediated by the first polynucleotide analogue indicates that the phenotype mediated by either polynucleotide analogue is sequence-specific.

Alternatively, a control polynucleotide analogue also can be used to confirm that a phenotype mediated by a first polynucleotide analogue is sequence-specific. A control

polynucleotide analogue is somewhat similar in sequence to the first polynucleotide analogue. The control polynucleotide analogue, however, has a number of bases that are dissimilar to the first polynucleotide analogue such that the control polynucleotide analogue is not sufficiently complementary and so will not anneal to the selected nucleic acid targeted by the first polynucleotide analogue. Therefore, no phenotype mediated by a control polynucleotide analogue is observed. A phenotype mediated by the first polynucleotide analogue that is not observed when the control polynucleotide analogue is used indicates that the phenotype mediated by the first polynucleotide analogue is sequence-specific. If a phenotype mediated by the control polynucleotide analogue is observed, then the phenotype mediated by the first polynucleotide analogue cannot be concluded to be sequence-specific.

In addition, a rescue mRNA encoding the polypeptide whose expression is reduced by a polynucleotide analogue can be used to show that a phenotype mediated by the polynucleotide analogue is sequence-specific. The rescue mRNA is introduced into the organism exhibiting the phenotype mediated by the polynucleotide analogue. Restoration of a wild type phenotype in place of the phenotype mediated by the polynucleotide analogue indicates that the phenotype mediated by the polynucleotide analogue is sequence-specific. A phenotype mediated by a morpholino-modified polynucleotide analogue that has been confirmed to be sequence-specific by a rescue mRNA or targeting with a second morpholino of unrelated sequence is referred to as a morphant phenotype. As used herein, the term “morphant” refers to an organism exhibiting a sequence-specific phenotype mediated by a morpholino-modified polynucleotide analogue.

4. Applications of polynucleotide analogues

Polynucleotide analogues can be used to determine the function of a coding sequence of, or a phenotype associated with, a selected nucleic acid of known sequence. Nucleic acids can be maternal or zygotic nucleic acids and can be involved in any biological process, for example embryogenesis and development, gene expression, regulation of gene expression, formation of particular differentiated tissues, cell signaling, and metabolic processes necessary for (1) embryogenesis and development, (2)

gene expression and its regulation, (3) formation of differentiated tissues, and (4) cell signaling. Nucleic acids of interest also are those associated with a disease condition. A nucleic acid that is associated with a disease condition can be one in which reduction in expression leads to a disease condition or alleviates a disease condition. A disease condition can result from any change, for example an increase or decrease, in the level of a biomarker such as a polypeptide, a nucleic acid, a lipid, any intracellular or extracellular molecule or compound, and the phosphorylated and unphosphorylated forms of a cellular molecule. A disease condition can result from, for example, excessive expression of a nucleic acid or expression of a mutated form of a nucleic acid thereby forming a product with aberrant activity.

To determine the function of the coding sequence of, or phenotype associated with, a selected nucleic acid of known sequence, a polynucleotide analogue is synthesized having a sequence complementary to the sequence of the selected nucleic acid. A polynucleotide analogue designed to have a sequence that is complementary to the sequence of a selected nucleic acid is said to “target” the selected nucleic acid. When the polynucleotide analogue is introduced into an organism, effects of the polynucleotide analogue on expression from the selected nucleic acid as well as associated phenotypes are examined.

Organisms useful for functional studies with polynucleotide analogues are those in which a polynucleotide analogue is able to distribute uniformly and inhibit expression from a selected nucleic acid in cells that express the selected nucleic acid. Organisms can be a fertilized or unfertilized egg, a cell in culture, an embryo, or a juvenile or an adult animal. An animal, for example, can be a fish, a frog, a mouse, a guinea pig, a sheep, a chimpanzee, or a human. Vertebrate organisms such as teleost eggs and embryos that undergo meroblastic cleavage can be used for functional studies with polynucleotide analogues. Cleavage refers to a series of mitotic divisions that occur in rapid succession as a fertilized egg is transformed into a multicellular embryo. The multicellular embryo consists of smaller nucleated cells referred to as blastomeres. In meroblastic cleavage, only a part of the egg is subdivided into blastomeres, in contrast to organisms that undergo holoblastic cleavage in which the entire egg is subdivided into blastomeres. The blastomeres generated from meroblastic cleavage are continuous with the remaining

uncleaved cytoplasm of the egg (see Balinsky *et al.* (1981) Cleavage in An Introduction to Embryology, 5th Edt. CBS College Publishing, pages 135-152). Examples of vertebrate organisms that undergo meroblastic cleavage, and therefore are useful model organisms for nucleic acid functional studies using polynucleotide analogues include the eggs and embryos of a zebrafish, a medaka, a pufferfish, and a stickleback.

Polynucleotide analogues can be used to determine the function of, or phenotype associated with, any nucleic acid of known sequence but unknown function. The nucleic acid can be one that is present, or one that is not present, in the model organism. To determine the function of, or phenotype associated with, any nucleic acid of known sequence but unknown function, the sequence of a homologue, orthologue, or paralogue that is present in the model organism is used. Homologues refer to nucleic acids encoding polypeptides having similar domains or structures that can be identified by nucleotide or amino acid sequence comparison. Homologues also can have similar activities. Orthologues refer to homologues that are from different species, while paralogues refer to homologues within one organism that have distinct expression patterns and therefore distinct biological roles. From the known sequence of a homologue, orthologue, or paralogue, a polynucleotide analogue targeting the homologue, orthologue, or paralogue is generated. The polynucleotide analogue targeting the homologue, orthologue, or paralogue is introduced into the model organism and the organism is assessed for a phenotype associated with reduction of expression of the homologue, paralogue, or orthologue. From the phenotype observed, the function of the homologue, paralogue, or orthologue can be determined, and in turn, the function of the newly discovered nucleic acid or its involvement in a particular aspect of the biology of the organism can be inferred.

Polynucleotide analogues also can be used to determine whether two nucleic acids are, or encode, genetic interactors. As used herein, the term “genetic interactors” refers to nucleic acids or polypeptides that function in a common metabolic process. As used herein, the term “metabolic process” refers to particular sets of metabolic processes involved in (1) embryogenesis and development, (2) gene expression and its regulation, (3) formation of differentiated tissues, (4) cell signaling, and (5) any other cellular and physiological processes. Genetic interactors, for example, can be nucleic acids such as

DNA or RNA, or the polypeptides encoded by nucleic acids. Genetic interactors can interact directly or indirectly.

To determine if two different nucleic acids are, or encode, genetic interactors, polynucleotide analogues that target the two nucleic acids can be used to reduce expression from the nucleic acids. A sequence-specific phenotype mediated by both polynucleotide analogues is compared to sequence-specific phenotypes mediated by each of the polynucleotide analogues. If the two different nucleic acids are genetic interactors, the phenotype mediated by both analogues is expected to be different than the “sum of the individual phenotypes” mediated by each of the analogues. That is, if the targeted nucleic acids encode two polypeptides that are genetic interactors, reduction in expression from both nucleic acids in an organism will result in either a synergistic effect on the phenotype mediated by the individual nucleic acids or a phenotype that is distinctly different from the “sum of the individual phenotypes.” In contrast, the targeted nucleic acids encode two polypeptides that are not genetic interactors if reductions in expression from both nucleic acids give rise to a phenotype that is “the sum of the individual phenotypes.”

Similarly, polynucleotide analogues also can be used to generate model organisms for the study of diseases. Disease conditions associated with loss or reduction of function of a particular nucleic acid in a higher organism such as a human can be generated in a model organism using a polynucleotide analogue if the model organism has a homologous or orthologous nucleic acid. For example, a polynucleotide analogue that targets the homologue or orthologue in the model organism is generated and introduced into the model organism. Reduction in expression of the homologue or orthologue results in a morphant organism that exhibits the disease condition. Morphants exhibiting a disease condition can be used to screen for compounds that are useful for treating the disease condition or alleviating the severity of the disease condition. To screen for compounds that are useful for treating a disease condition or alleviating the severity of the disease condition, morphants exhibiting the disease condition can be contacted with candidate compounds and then assessed to determine whether the disease condition is lessened.

Polynucleotide analogues also can be used to identify nucleic acids not known to be associated with a disease condition. To identify nucleic acids not known to be associated with a disease condition, various polynucleotide analogues are introduced into wild type organisms and morphants exhibiting any particular disease condition are chosen for further analysis. A collection of polynucleotide analogues, for example, can be used to generate a collection of morphants. Those morphants that exhibit a particular disease condition can be used to identify drug targets as well as to develop novel treatments for the disease condition. A potential drug target, for example, is identified as the nucleic acid whose reduction in expression led to the disease condition. A morphant that exhibits a particular disease condition can be used to screen for novel treatments for the particular disease condition as described earlier.

To identify nucleic acids whose excessive activity leads to a disease condition, polynucleotide analogues are introduced into organisms exhibiting the disease condition. Those organisms whose disease state is lessened by the polynucleotide analogue are further examined to identify nucleic acids whose expressions have been reduced. These nucleic acids are identified as useful targets for the development of novel treatments for the particular disease.

Polynucleotide analogues also can be used therapeutically as treatments for disease conditions. For example, a polynucleotide analogue can be used to treat disease conditions associated with excessive expression of a particular nucleic acid or expression of a culprit nucleic acid. Multiple polynucleotide analogues, for example, that target the same culprit nucleic acid and have synergistic effects in alleviating the disease phenotype can be useful for circumventing toxicity associated with treatment using one analogue, since lower amounts of analogues can be used.

5. The morpholino-modified polynucleotide analogue/zebrafish system

An example of a system that is useful for determining function or phenotype associated with a selected nucleic acid of known sequence is the morpholino-modified polynucleotide analogue/zebrafish system.

Morpholinos (morpholino-modified polynucleotide analogues) are not subjected to any known endogenous enzymatic degradation activity. Morpholinos have been

shown to bind to and block translation of mRNA both *in vitro* and in tissue culture (Summerton (1990) *Biochim Biophys Acta* 1489:141-158; Summerton and Weller (1997) *Antisense Nucleic Acid Drug Dev* 7:187-195). This approach makes morpholino targeting highly predictable for polynucleotide design and significantly reduces non-specific effects. In contrast, traditional antisense polynucleotide approaches utilize RNAse-H-based degradation of mRNA as a mechanism of action. RNAse-H mediated strategies, however, have been tried with only modest success (Barabino *et al.* (1997) *Mech Dev* 63:133-143). Furthermore, in fish, single stranded polynucleotides tend to be toxic or there is an inability to achieve uniform distribution among all cells of the organism.

In the following sections, the examples describing the use of morpholinos in zebrafish show these compounds to be (1) sequence specific and (2) extremely potent in all cells for at least the first 50 hours of development in F0 zebrafish embryos as targeted gene 'knockdown' agents. This period in the zebrafish embryonic development includes the fundamental vertebrate processes of segmentation and organogenesis. This tool offers the opportunity to pursue sequence-specific gene targeting studies without the necessity of laborious, time consuming, and expensive F3 vertebrate genetic testing. Morpholinos, thus, offer a high throughput F0 vertebrate assay system for vertebrate functional genomics applications.

The use of morpholino-based gene targeting represents a new tool in the genetic repertoire of vertebrate biologists and, combined with the excellent embryology of the zebrafish, is extremely powerful in the elaboration of gene function for similarly conserved developmental processes.

6. Methods of administration

Polynucleotide analogues can be introduced into a model organism by methods used to introduce single stranded mRNA into the model organism. (See Hyatt and Ekker (1999) *Methods in Cell biology* 59:117-126). Examples of delivery methods include (1) microinjection and (2) simply exposing the model organism to the polynucleotide analogue. Polynucleotide analogues can be delivered in water or a suitable buffer. A suitable buffer is one in which the polynucleotide analogue can be dissolved and that is

non-toxic to the model organism to which the polynucleotide analogue is to be delivered. A non-toxic buffer can be one that is isotonic to, or one that has a pH similar to the physiological pH of, an organism to which the polynucleotide analogue is to be delivered. A buffer that is isotonic with an organism is one that has the same osmolarity as the organism. Danieau solution, for example, is isotonic with the model organism zebrafish. A pH similar to the physiological pH of the organism can be 2.5 pH units below or above the pH of the organism. A polynucleotide solution prepared for delivery into zebrafish, for example, can have a pH that is 5, 5.4, 5.7, 6, 6.2, 6.6, 7, 7.4, 7.8, 8, 8.6, or any value in between these.

Different polynucleotide analogues can be introduced into the model organism as a mixture. Alternatively, different polynucleotide analogues can be introduced sequentially by multiple exposures or injections.

7. Compositions and kits

The invention provides compositions of individual polynucleotide analogues in a suitable buffer. The invention also provides for compositions of at least two polynucleotide analogues in a pharmaceutically acceptable carrier.

Compositions can be in the form of tablets, capsules, powders, solutions, suspensions, or emulsions depending on the route of administration. Compositions can contain sterile pharmaceutically acceptable carriers or excipients. Common pharmaceutically acceptable carriers or excipients can be aqueous or non-aqueous. Aqueous carriers include, without limitation, water, alcohol, saline, and buffered solutions. Examples of non-aqueous carriers include, without limitation, propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters. Preservatives, flavorings, sugars, and other additives such as antimicrobials, antioxidants, chelating agents, inert gases, and the like also may be present.

For administration by injection, a solution can be prepared using a suitable non-toxic buffer, i.e. one that is similar in pH, is isotonic, or both similar in pH and isotonic, to a selected organism.

For oral administration, tablets or capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g.,

pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). Tablets can be
5 coated by methods known in the art. Preparations for oral administration also can be formulated to give controlled release of a polynucleotide analogue. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxethylene-polyoxypropylene copolymers are examples of excipients for controlling the release of a polynucleotide analogue of the invention *in vivo*.

10 For nasal administration, preparations can be in the form of a liquid solution, a gel, or a dry product. Inhalation formulations may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, and may contain excipients such as lactose, if desired. Nebulised aqueous suspensions or solutions can include carriers or excipients to adjust pH and/or tonicity. Nasal drops can be
15 administered in the form of oily solutions.

For parenteral administration, liquid solutions or suspensions in aqueous physiological buffer solutions can be prepared as desired using standard methods. Formulations may contain common excipients as well as glycocholate for buccal administration. Suitable parenteral delivery systems include ethylene-vinyl acetate
20 copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.

The invention also provides kits comprising a collection of different polynucleotide analogues, for example, morpholino-modified polynucleotides. The collection of polynucleotide analogues can be analogues directed to nucleic acids of the entire genome of an organism. The collection of polynucleotide analogues also can be
25 directed to nucleic acids involved in a common biological process such as, for example, a disease condition, regulation of nucleic acid expression, or a common metabolic, developmental, or signaling pathway.

The invention also provides a collection of morphants that can be generated using the collection of different polynucleotide analogues. Morphants can be models of human
30 diseases such as prophyria or cyclopia. Morphants also can be defective in a

differentiated tissue, for example, vasculature, blood, an organ, or a specialized cell type such as fibroblasts, neurons, and epithelial cells.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

5

EXAMPLES

Example 1 - Zebrafish care and egg collection

Standard zebrafish care protocols are described in Westerfield (1995) The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (*Brachydanio rerio*) 3rd Edition, University of Oregon Press.

10

Zebrafish were kept in 6.5 gallon (26 liters) and 20 gallon (76 liters) plastic tanks at 28 °C. A 6.5 gallon tank housed 25 fish and a 20 gallon tank housed 70 fish. Tank water was constantly changed with carbon-filtered and UV-sterilized tap water (system water) at a rate of 15 to 40 mL/min. Alternatively, tank water was replaced each day by siphoning up debris from the bottom of the tank. Tap water, aged a day or more in an open (heated) tank to release chlorine, was adequate. More consistent conditions, however, were obtained by adding commercial sea salts to deionized or distilled water (60 mg of 'Instant Ocean' salt per liter of water, see Westerfield (1995) The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (*Brachydanio rerio*) 3rd Edition, University of Oregon Press). A 10-hour dark and 14-hour light day cycle was maintained in zebrafish facility.

15

20

Fish were fed brine shrimp twice a day. To make shrimp, 100 mL of brine shrimp eggs were added to 18 L of salt water (400 mL of 'Instant Ocean' salt per 18 L of water) and aerated vigorously. After 2 days at 28 °C, the shrimp were filtered through a fine net, washed with system water, suspended in system water, and fed to fish. Alternatively, fish could also be fed with 'Tetra' brand dry flake food.

25

Zebrafish spawning was induced every morning shortly after sunrise. To collect the eggs, a 'false bottom container' system was used (Westerfield (1995) The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (*Brachydanio rerio*) 3rd Edition, University of Oregon Press). The system consisted of two containers of approximately 1.5 L, one slightly smaller than the other. The bottom of the smaller container was

30

replaced with a stainless steel mesh with holes bigger than the diameter of zebrafish eggs. The smaller container was then placed into the bigger container, and the setup was filled with system water. Up to eight zebrafish were placed inside the smaller container. When the fish spawn, the eggs fall through the mesh into the bigger container, and in this way, the eggs cannot be reached by the fish and eaten. About 10-15 minutes were allowed for spawning, after which time the smaller container with the fish was transferred into another bigger container. The eggs were collected by filtering using a mesh with the holes smaller than the diameter of the eggs. Fish were used once a week for optimal embryo production.

Example 2 – Zebrafish and Xenopus strains

The zebrafish E-line transgenic line contained a single copy of the pT-EF1 α -GFP-pA transposon at the E-line locus (Nasevicius and Ekker (2000) *Nature Genetics* 26:216-220). Heterozygous E-line embryos were obtained from an outcross of homozygous E-line adults and can be obtained S. C. Ekker, University of Minnesota Medical School, Minneapolis, MN.

Example 3 – Polynucleotide analogues

Morpholino phosphorodiamidates antisense oligonucleotides (morpholinos or MOs) were purchased from Gene-Tools, LLC (Corvallis, OR). MO sequences were designed based on parameters recommended by the company. MOs were 21 to 25-bases in length, had no predicted internal hairpins, and consisted of approximately 50 % G/C and 50 % A/T residues. Sequences having four consecutive G nucleotides were avoided. All MOs were designed to bind to 5' untranslated regions (UTRs), or regions flanking and including sequence encoding the initiating methionine.

FITC-labeled 14-mer peptide nucleic acids (PNAs) were obtained from Applied Biosystems. Rhodamine-labeled 25-mer PNAs were a gift from Dr. D. Corey, University of Texas Southwestern. 2'-O methyl RNAs were obtained from Integrated DNA Technologies, Inc. Phosphoramidates were obtained from Annovis, Inc.

Solutions of polynucleotide analogues were prepared and injected as described in Example 4.

Sequences of the polynucleotide analogues used were as follows. Residues complementary to the predicted start codon are underlined in all cases.

FITC-labeled MO, FITC-labeled 3'-5' phosphoroamidate, and FITC-labeled 2'-O methyl

RNA: 5' - ATC CAC AGC AGC CCC TCC ATC ATC C- 3' (SEQ ID NO: 1)

FITC-labeled PNA-1: 5' -AGC AGC CCC TCC AT- 3' (SEQ ID NO: 2)

FITC-labeled PNA-2: 5' -TCTCTCTC-O-nJTJTJTJT- 3' (SEQ ID NO: 3)

Negative control-MO sequence [unlabeled or FITC-labeled at the 3' end]:

5'-CCTCTTACCTCAGTTACAATTATA-3' (SEQ ID NO: 4)

chordin-MO [FITC-labeled at the 3' end] and chordin-PNA [rhodamine-labeled]:

5' ATCCACAGCAGCCCCTCCATCATCC-3' (SEQ ID NO: 5)

GFP-MO: 5'-TCTTCTCCTTTACTCATTTTCTACC-3' (SEQ ID NO: 6)

GFPD4-MO: 5'-TCTaCTCgTTTACTCATTaTCTtCC-3' (SEQ ID NO: 7)

oep-MO: 5'-GCCAATAAACTCCAAAACAACCTCGA-3' (SEQ ID NO: 8)

ntl-MO: 5'-GACTTGAGGCAGGCATATTTCCGAT-3' (SEQ ID NO: 9)

shh-MO #1: 5'-CAGCACTCTCGTCAAAAGCCGCATT-3' (SEQ ID NO: 10)

shh-MO #2 : 5'-TGTCTAGCAGGGTTTCTCGTTGTCG-3' (SEQ ID NO: 11)

twhh-MO: 5'-TTCCATGACGTTTGAATTATCTCTT-3' (SEQ ID NO: 12)

nacre-MO and nacre-PNA [rhodamine-labeled]:

5'-CATGTTCAACTATGTGTTAGCTTCA-3' (SEQ ID NO: 13)

sparse-MO: 5'-TATAAGTCCATCTATCTCATGTGTG-3' (SEQ ID NO: 14)

urod-MO: 5'-GAATGAAACTGTCCTTATCCATCA-3' (SEQ ID NO: 15)

VEGF-A-1: 5'-GTATCAAATAAACAACCAAGTTCAT-3' (SEQ ID NO: 16)

VEGF-A-1D4 [four base mismatch]:

5'-GTAAcAAATAAACAACCAATGTTgAT-3' (SEQ ID NO: 17)

VEGF-A-3: 5'-TAAGAAAGCGAAGCTGCTGGGTATG-3' (SEQ ID NO: 18)

ztsgl-MO: 5'-CTGATGATGATGATGAAGACCCCAT-3' (SEQ ID NO: 19)

- zfp2MO-ATG: 5'-CACACACACTTCCACTCGCCTGCAT-3' (SEQ ID NO: 20)
 zfpMO-UTR: 5'- CCTGCATTGTCTCGAAAAGTTCCGC-3' (SEQ ID NO: 21)
 Fli-1-UTR MO: 5'-CAATTTTCAGTGGAGCCCGACAATA-3' (SEQ ID NO: 22)
 Fli-1-ATG MO: 5'-TAATAGTTCCGTCCATTTTCCGCAA-3' (SEQ ID NO: 23)
 5 Fli-1.3 MO: 5'-TCCGTCCATTTTCCGCAATTTTCAG-3' (SEQ ID NO: 24)

Example 4 – Injections of polynucleotide analogues

The analogues MOs, 2'O-methyl RNA, and 3' –5' phosphoroamidate were solubilized in water at a concentration of 8 mM (approximately 65 mg/ml). The resulting stock solution was diluted to working concentrations of 0.09 to 3.0 mg/ml in water or 1 X Danieau solution (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO₄, 0.6 mM Ca (NO₃)₂, 5 mM HEPES pH 7.6). Analogue solutions were injected into the yolk as described in Ekker *et al.* (1995) *Curr Biol* 5:944-955. Analogue injections were performed using a method similar to that used for mRNA injections. Briefly, zebrafish eggs were collected and transferred onto agarose plates as described in Westerfield (1995) The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (*Brachydanio rerio*) 3rd Edition, University of Oregon Press. While agarose plates for mRNA injections were kept cold to slow embryo development, the plates for analogue injections were prewarmed to approximately 20 °C, since analogue injection into cold embryos were found to increase non-specific effects and mortality of the injected embryos.

Needles used for analogue injections were the same as for mRNA injections (Hyatt and Ekker (1999) *Methods in Cell Biology* 59:117-126). The needles were back-filled with a pipette and calibrated by injecting the loaded morpholino solution into a glass capillary tube. The picoinjector volume control was then setup for 1.5 to 15 nL. The injection volume depended on the required dose, usually 1.5 to 18 ng of analogue was injected. Analogue solutions were injected through the chorion into the yolk of zebrafish embryos. The injected embryos were transferred to petri dishes containing system water and allowed to develop at 28 °C.

Injections of buffered Danieau-MO solutions resulted in lower mortality rates in injected embryos compared to injections of water-MO solutions. No difference in the penetrance of the observed phenotypes, however, was seen between embryos injected

with buffered Danieau or water solution. The injection volume was 1.5 nL to 15 nL for all analogues depending on the required injected dose. For wild type or heterozygous E-line embryos of 1 to 16 cell stages, analogues were injected into the yolk.

Embryos that received two different MOs were injected twice, one injection for each MO. In experiments involving injection of two different MOs, embryos injected with only a single MO were analyzed and compared with embryos injected with two different MOs.

Effective doses were determined separately for each analogue. For example, at the effective dose of 4.5 ng and lower for the GFP-MO, reduction of GFP protein was detected, and $\geq 90\%$ of the GFP-MO-injected embryos developed normally as assayed using standard morphological criteria. Higher doses of the GFP-MO resulted in a larger average reduction of GFP protein, but also caused some detectable detrimental effects on development. These higher doses were not pursued further for this MO. In all cases shown, the dose used for analysis resulted in embryos of two classes, those displaying a specific phenotype or those that were normal when assessed using morphological criteria. A small fraction of embryos (typically $\leq 5\%$) developed abnormally due to mechanical damage following microinjection. Penetrance number for a specific MO and concentration was assessed by examining morphology of injected embryos. A minimum sample size of 25 was used.

PNAs (chordin and nacre 25-mer PNAs) were diluted in water to a concentration of 0.25 mg/ml (resulting in a solution with final pH = 5). The resulting solutions were incubated at 55°C for 5 minutes and placed on ice. The PNA solutions were injected into the yolk of zebrafish embryo as described for morpholino phosphorodiamidate (MO), 2'O-methyl RNA, and other injections. In contrast to work with MOs, PNAs display a mosaic distribution if injected later than the 4-cell stage. Furthermore, precipitation of a significant fraction of the injected PNA at the site of injection was observed in the injection of PNA at doses of 1.5 ng per embryo or higher.

Example 5 - mRNA injections

Synthetic mRNA was injected, as described in Ekker *et al.* (1995) *Curr Biol* 5:944-955, into the yolk of zebrafish embryos previously injected with the indicated MO.

Siblings from the same pool of MO-injected embryos served as internal controls for these experiments.

For *Xenopus*, mRNA microinjections were performed at the 4-cell stage using 0.3 X MMR, 3.5 % ficoll. Dorsal-ventral polarity of early cleavage stage embryos was
5 determined using pigmentation differences (Cho *et al.* (1991) *Cell* 67:111-120).

Synthetic mRNAs were designed such that any overlap between the synthetic mRNA and the MO would be insufficient for MO targeting. The *oep* mRNA used did not contain any overlap with the *oep*-MO. The *twhh* mRNA used contained only a six base overlap with *twhh*-MO, a degree of overlap previously shown to be insufficient for
10 MO targeting *in vitro* and in tissue culture studies (Summerton (1999) *Biochim Biophys Acta* 1489:141-158 and Summerton *et al.* (1997) *Antisense Nucleic Acid Drug Dev* 7:187-195). *Chordin* mRNA from *Xenopus* was used in order to avoid any sequence homology with the zebrafish *chordin*-MO, and because previous studies showed *Xenopus* and zebrafish *chordin* genes encoded equivalent specific activities in *Xenopus* embryos
15 (Miller-Bertoglio *et al.* (1998) *Dev Biol* 214:72-86).

Example 6 – FITC-dextran injections, tissue sectioning, and visualization

Microangiography was performed as described in Weinstein *et al.* (1995) *Nat Med* 1:1143-7. Fluorescein isothiocyanate-dextran (FITC-dextran) having a molecular
20 weight of 2,000,000 Daltons (SIGMA, catalog #FD-2000S) was used for these studies. The dextran was solubilized in 1 X Danieau solution at 2 mg/ml concentration. Approximately 10 µl of the prepared solution was injected into sinus venosa / cardinal vein of anesthetized 48-hour embryos.

Embryos injected with FITC-dextran were fixed overnight, embedded into
25 paraffin using standard procedures, and sectioned. Histological haematoxylin-eosin staining of the sections was subsequently carried out using standard protocols.

Both FITC-dextran injected embryos and unprocessed tissue sections (i.e. unstained sections) were visualized using a ZEISS Axioskop 2 microscope with a standard FITC filter set.

Example 7 – Digital photography

Bright field and *in situ* photography were performed on a ZEISS Axioplan 2 microscope using Nikon CoolPix 990 (bright field) or Kodak DCS 420 (*in situ*) digital cameras. For fluorescent photography, a ZEISS AxioCam or a Nikon CoolPix 990 digital camera was used.

Example 8 - Fluorescence analysis

Embryos injected with FITC-labeled antisense polynucleotide analogues were analyzed using FITC filters on a Zeiss Axioplan2 fluorescence microscope. Images were obtained using a Kodak DCS420 Digital Camera.

Fluorescence pictures of groups of embryos were taken using a MICROIMAGE I30B Low Light Integrating Camera and captured using a DC30+ analogue to digital video capture board (Pinnacle Systems) at maximum resolution (640 x 480) settings. Signal intensities were set to sub-saturation levels for maximal information capture. Sub-saturation level of signal intensity was determined using uninjected E-line embryos. Fidelity of capture was confirmed by simultaneously imaging both analogue and digital video shots. The resulting images were imported into Adobe Photoshop 5.0 for quantitative analysis. The background for each image, established using the "Selective Color" algorithm, was set to the same setting in all images. The "Mean" value of the "Histogram" algorithm was used to measure the green channel signal; the other channels were removed to minimize non-specific background. All scores were normalized to the values obtained from uninjected E-line (100 %) and wild type (0 %) data points.

Example 9 – Western, northern, and *in situ* hybridization analyses

For detection of GFP or NTL protein, standard western analysis was performed using GFP antibody (Clontech) or NTL antibody (gift of S. Schulte-Merker). Proteins isolated from pools of injected embryos were used. The amount of protein analyzed per sample was equivalent to the amount of protein obtained from five embryos.

For antibody staining, rabbit anti-phospho Mad antibody, a gift from P. ten Dijke, was used at 1/2000 dilution. Staining was visualized using an alkaline phosphatase-coupled secondary antibody (Promega laboratories).

For detection of GFP mRNA, Northern blot hybridization was performed according to standard procedures. A 700 base pair fragment from a *Pst* I digest that corresponded to the GFP coding region was used as probe. Each sample analyzed consisted of 5 µg total RNA isolated from a pool of 30 embryos. Two independent analyses were performed.

For whole-mount *in situ* hybridization, methods described by Mason *et al.* (1994) *Genes and Development* 8:1489-1501 and Jowett (1999) *Methods in Cell Biol* 59:63-85 were used. Hybridization was performed at 65 °C. T7 polymerase was used for riboprobe synthesis. Riboprobes for *fli-1* and *flk-1* were synthesized using plasmids zffli-1 and zfflk-1 (Thompson *et al.* (1998) *Dev Biol* 197:248-69) digested with *EcoR* I and *Sma* I, respectively.

Example 10 – Uniform distribution of injected modified polynucleotide analogues in early zebrafish embryos

The delivery efficiency of modified polynucleotide analogues was determined using FITC-labeled analogues. FITC-labeled modified polynucleotide analogues were injected into embryos at the 1-2-cell stage. Modified polynucleotide analogues that were injected included MOs, peptide nucleic acids (PNA), 2' -O methyl RNA, and 3'-5' phosphoroamidate. Distribution of FITC-labeled polynucleotide analogues was examined by fluorescence microscopy as described in Examples 7 and 8. Injected embryos were compared with uninjected control embryos. Results demonstrate that polynucleotide analogues were completely translocated to blastomeres as early as the 8-cell stage (less than 1 hour after injection). Polynucleotide analogues remained uniformly distributed among blastomeres as evident from samples at the mid-blastula stage.

In a second distribution study, 90 pg of FITC-labeled control-MO or FITC-labeled chordin-MO were injected into wild type zebrafish embryos from 1 to 16 cell stages of development. Uniform distribution of FITC-labeled-MOs was achieved at sphere and 28 hour stages. Injection of a chordin-MO dose of 90 pg resulted in embryos that developed normally.

In a third distribution study, FITC-labeled PNA-2 (Gene Therapy Systems) was

microinjected into yolks of 1-16 cell zebrafish embryos. Injection volumes were 6 to 15 nl; approximately 50-200 ng was injected. Buffer from Gene Therapy Systems or 0.5 X Danieau buffer was used. Toxicity was not observed with either buffer. From 85-90 % of the injected embryos survived at 48 hours of development (usual survival rate for non-toxic injections). Older embryos were not analyzed. The fluorescence signal was detected in all tissues at comparative levels. The distribution was uniform as determined by fluorescence microscopy. Isolated points of high signal concentration, however, were observed (< 10 per embryo, at approximately 1 cell diameter).

Example 11 – Specific inhibition of GFP transgene expression in all cells of a zebrafish embryo by GFP-MO

A non-essential ubiquitous GFP transgene was used to test the applicability of antisense MOs as a general gene knockdown strategy in zebrafish. A GFP-targeted MO (GFP-MO) was injected into zebrafish E-line embryos. Fluorescence and western blot assays were used to examine GFP transgene expression. GFP fluorescence of (1) uninjected E-line embryos, (2) E-line embryos injected with 4.5 ng of control-MO, (3) E-line embryos injected with 4.5 ng of GFP-MO, and (4) wild type embryos was compared by FITC illumination. GFP fluorescence in uninjected E-line embryos was ubiquitous. Similarly, GFP fluorescence in E-line embryos injected with 4.5 ng of a control-MO or a four base mismatch GFP-MO (GFPD4-MO) was near wild type. In contrast, GFP transgene expression was inhibited in all cells of the zebrafish E-line embryo injected with 4.5 ng of GFP-MO. The specific loss of GFP signal in embryos injected with GFP-MO was noted in nine separate experiments; at least 30 embryos were assayed in each experiment. The lack of visible GFP fluorescence indicated that a nearly complete loss of GFP protein expression was achieved. Furthermore, GFP-MO inhibition of GFP expression was dose-dependent. Figure 1 is a GFP fluorescence inhibition graph demonstrating sequence-specific and dose-dependent inhibition of GFP expression. GFP activity in embryos injected with the control-MO and in embryos injected with the GFP-MO was compared. Fifteen embryos were assayed for each data point shown. Fluorescence activity data were confirmed by western blotting. These data demonstrate

that specific inhibition of gene expression in all cells of the 28-hour zebrafish embryo was achieved using MOs.

Example 12 – Inhibition of Chordin Expression by Chordin-MO

5 A *chordin* antisense MO (chordin-MO) was injected into zebrafish embryos and a highly specific series of phenotypes dependent upon dose was observed in 28-hour embryos and 3-day old embryos. Embryos injected with various amounts of chordin-MO were compared with wild type embryos. The numbers of embryos injected with particular amounts of chordin-MO were as follows: 169 embryos were injected with 0.09
10 ng MO; 97 embryos were injected with 0.9 ng MO; 399 embryos were injected with 1.5 ng MO; 423 embryos were injected with 4.5 ng MO; and 224 embryos were injected with 9 ng MO. Figure 2 is a graph demonstrating that two chordin-MO phenotypes, weak and strong, were achieved with increasing doses of chordin-MO injected. At low doses, a weak chordin-MO phenotype, the equivalent of a reduced *chordin* loss of function
15 phenotype, was noted. Embryos displaying the weak chordin-MO phenotype had partially expanded blood islands, u-shaped somites, and abnormal tail fins with multiple folds. At higher doses, chordin-MO injected embryos exhibited a phenocopy of *chordin* null mutant embryos (Fisher *et al.* (1997) *Development* 124:1301-1311; Hammerschmidt *et al.* (1996) *Development* 123:95-102), i.e. the strong chordin-MO phenotype. This
20 strong chordin-MO phenotype was observed at high frequency in high dose injections (≥ 75 % at 4.5 ng MO injection, n=423), and consisted of abnormal u-shaped somites, extremely expanded blood islands, abnormal tail fins, and reduced heads. About 80 % of the epiboly embryos subjected to *in situ* hybridization for *otx-2* showed reduction of *otx-2* consistent with head reduction. About 65 % of epiboly embryos subjected to *in situ*
25 hybridization for *gata-2* showed that the *gata-2* expression domain was greatly enlarged and shifted anteriorly, indicating ventralization of the mesoderm. (*Gata-2* was expanded in 100 % of the injected embryos; n=30). Comparison of injected embryos with uninjected embryos demonstrated posterior fusion of *gata-2* expression stripes. These results demonstrate that the equivalent of an allelic series for the loss of the *chordin* gene
30 was achieved by the use of different doses of the chordin-MO.

Whole-mount *in situ* hybridization for *chordin* mRNA was performed. Comparison of injected and uninjected embryos demonstrated that *chordin* mRNA levels were similar. Therefore, inhibition of *chordin* function by *chordin*-MO was not mediated by the conventional RNaseH mediated antisense-targeted degradation of *chordin* mRNA.

To verify the specificity of gene targeting by *chordin*-MO, embryos were injected with synthetic *Xenopus chordin* mRNA to determine if effects of *chordin*-MO can be reversed. When 423 embryos were injected with 4.5 ng of *chordin*-MO, 76 % showed the strong *chordin* phenotype. In contrast, when 30 embryos were injected with 4.5 ng of *chordin*-MO and 300 pg of *Xenopus chordin* mRNA, 10 % exhibited the strong *chordin* phenotype. Figure 3 is a graph demonstrating that the *chordin*-MO phenotype was partially rescued by *Xenopus chordin* mRNA injection, thereby illustrating specificity of *chordin*-MO targeting.

Example 13 - Inhibition of *chordin* expression by *chordin*-PNA

Twenty-five-base *chordin*-PNA (chd-PNA) and *nacre*-PNA were injected into zebrafish embryos as described in Example 4. Injected embryos were compared to wild type embryos. The resulting phenotypes were observed in 28-hour old embryos.

The numbers of embryos injected with particular amounts of *chordin* PNA were as follows: 41 embryos were injected with 0.25 ng chd-PNA; 130 embryos were injected with 0.5 ng chd-PNA; 98 embryos were injected with 1 ng chd-PNA; 77 embryos were injected with 1.5 ng chd-PNA. The numbers of embryos injected with particular amounts of *nacre*-PNA were as follows: 38 embryos were injected with 0.25 ng *nacre*-PNA, 71 embryos were injected with 0.5 ng *nacre*-PNA; 78 embryos were injected with 1 ng *nacre*-PNA; 75 embryos were injected with 1.5 ng *nacre*-PNA.

A weak ventralization, equivalent to the weak phenotype observed in chd-MO injection, was observed in 13 % of the embryos injected with 0.25 ng of chd-PNA. Non-specific effects were noted in 6 % of the injected embryos, while mortality rate was 22 %. In the embryos injected with 0.5 ng chd-PNA, 31 % mortality rate was observed. About 38 % of the injected embryos exhibited a weak ventralization phenotype, while 2 % exhibited a strong ventralization phenotype similar to a null *chordin* mutant phenotype. Non-specific effects were observed in 43 % of the injected embryos. Injection with 1 ng

and 1.5 ng of chd-PNA resulted in 74 % and 76 % mortality rates, respectively. The injection phenotypes were not analyzed.

Epiboly stage embryos were subjected to *in situ* hybridization to confirm morphological results. These analyses indicated that 28 % of the chd-PNA injected embryos had expanded gata-2 expression, a hallmark of mesoderm ventralization. *In situ* hybridization for otx-2 showed that 50 % of zebrafish embryos injected with 0.5 ng chd-PNA and 70 % of zebrafish embryos injected with 1 ng and 1.5 ng chd-PNA had reduced otx-2 expression. Reduction of otx-2 expression is indicative of embryo ventralization by the chd-PNA.

Nacre-PNA injections resulted in low to moderate mortality rates. Injections of 0.25 ng, 0.5 ng, 1 ng, and 1.5 ng of nacre-PNA resulted in mortality rates of 12 %, 24 %, 36%, and 35 %, respectively. Non-specific abnormality rates ranged from 3 % for injections of 0.25 ng and 0.5 ng to 12 % for injection of 1.5 ng of nacre-PNA. No ventralization phenotype was observed in embryos injected with nacre-PNA. Furthermore, analysis of 2 day-old zebrafish embryos showed that injection with nacre-PNA had no effect on the nacre gene activity. *In situ* hybridization analysis of injected embryos showed that nacre-PNA injection did not alter gata-2 or otx-2 expression. These results indicate that the ventralization phenotype is specific to chordin-PNA.

Example 14 – Inhibition of maternal gene expression by oep-MO

The *one-eyed pinhead* gene (*oep*) (Zhang *et al.* (1998) *Cell* 92:241-251) was selected to test for maternal gene activity inhibition by MO. Embryonic *oep* function is due to both maternal and zygotic genetic contributions that are distinguishable based on specific criteria (Gritsman *et al.* (1999) *Cell* 97:121-132). Embryos deficient in *oep* function are defective in signaling through the *nodal* pathway. Embryos were injected with 9 ng of oep-MO, and phenotypes consistent with loss of zygotic *oep* function were seen. Cyclopia and ventral curvature typical of zygotic *oep* mutants were observed in 30 ± 5 % of embryos (n=291). In 13 ± 5 % of embryos (n=291), severe cyclopia, somite absence in the trunk, misshapen tail somites, and reduced notochord typical of a maternal-zygotic *oep* mutant were observed. Tailbud stage embryos were subjected to *in*

situ hybridization for *pax-2* and *axial*. Prechordal mesoderm reduction was seen in 45 % of injected embryos when compared to wild type embryos; 24 embryos were analyzed.

The *oep*-MO phenotype was rescued by injection with synthetic zebrafish *oep* mRNA. Forty-three percent of embryos (n=291) displayed *oep* phenotypes when injected with 9 ng *oep*-MO, while none of the 33 embryos analyzed displayed *oep* phenotypes when injected with 9 ng *oep*-MO and 50 pg *oep* mRNA. Figure 4 is a graph demonstrating dose-dependent reduction in the frequency of the *oep* phenotype in response to *oep* mRNA injections. This result demonstrates that the observed *oep* phenotype was due to the specific inhibition of *oep* gene function.

10 Injections with higher concentrations of *oep*-MO resulted in a phenocopy of the loss of both zygotic and maternal *oep* functions. MOs are thus capable of targeting maternal gene function, albeit at reduced levels compared to zygotic gene targeting.

Example 15 – Use of morpholinos to identify genetic interactors

15 An MO targeted to the *no tail (ntl)* gene (Schulte-Merker *et al.* (1994) *Development* 120:1009-1015) was used to identify genetic interactors of *ntl*. Embryos (n=118) were injected with 9 ng of *ntl*-MO. Ninety-eight percent of the injected embryos were indistinguishable from those caused by a null mutation (Halpern *et al.* (1997) *Dev Biol* 187:154-170) when assessed using molecular and phenotypic criteria. Normal head, abnormal somites, and extremely reduced tail were prominent. When *ntl*-MO was injected into *ntl* mutant embryos (n=72), no additional defect was noted in the *ntl* mutant embryos due to the injection of *ntl*-MO. NTL protein was specifically and quantitatively reduced in wild type embryos injected with *ntl*-MO.

25 Activation of the somitic mesodermal marker *myod* requires input from both *oep* and *ntl* pathways (Schier *et al.* (1997) *Development* 124:327-342). When embryos were co-injected with 9 ng of *ntl*-MO and 9 ng of *oep*-MO, highly reduced head, reduced tail, and extremely reduced somites and notochord were observed. When 10-12 somite embryos were subjected to *in situ* hybridization for *myod*, embryos reduced in either *ntl* or *oep* function displayed an altered but robust expression of *myod*, while embryos reduced of both functions expressed *myod* in only a few cells. For example, 92 % of *ntl*-MO injected embryo (n=25) exhibited adaxial mesoderm reduction and posterior somite

fusion, and 41 % of oep-MO injected embryos (n=22) exhibited posterior fusion of the adaxial mesoderm. In ntl-MO and oep-MO co-injected embryos (n=24), 52 % exhibited no adaxial mesoderm and extremely reduced somitic mesoderm.

Whole-mount *in situ* hybridization of *shh* in 10-12 somite stage embryos demonstrated that 80 % ntl-MO injected embryos (n=25) exhibited weak expansion of *shh* expression, while 50 % of oep-MO injected embryos (n=22) exhibited strong expansion of the *shh* expression. Fifty-two percent of embryos co-injected with ntl- and oep-MO (n=31) exhibited severe reduction of *shh* expression. Figure 5 is a graph comparing the frequencies of *ntl*, *oep*, and *ntl* and *oep* phenotypes observed in embryos injected with ntl-MO, oep-MO, or both MOs. MOs are thus effective tools for the testing of genetic interactions *in vivo*.

Example 16 – Inhibition of gene expression throughout somitogenesis and organogenesis

Later-acting genes were used to determine the perdurance of morpholino effects. One hundred and twelve embryos were injected with 9 ng of nacre-MO. Ninety-eight percent of injected embryos exhibited a characteristic and nearly complete loss of body pigmentation through the first 50 hours of development, a phenotype indistinguishable from that observed in the *nacre* mutant (Lister *et al.* (1999) *Development* 126:3757-3767). At later time points, pigmentation returned at a variable rate. One hundred and fifty-nine embryos were injected with 9 ng of sparse-MO. Injection of sparse-MO duplicated a known zebrafish pigment mutation *sparse* (Parichy *et al.* (1999) *Development* 126:3425-3436). When 65-hour and 10-day old zebrafish embryos were examined, 95 % exhibited reduced numbers of pigmented cells (melanocytes). Dorsal melanocytes were significantly reduced in these embryos. Therefore, MO-based gene targeting was completely penetrant throughout the first two days, and potentially the first 10 days, of development. Furthermore, MO-based gene targeting was completely penetrant throughout the critical vertebrate processes of somitogenesis and organogenesis in the zebrafish embryo.

Example 17 – Development of morpholino-based model systems for human diseases

Hepatoerythropoietic porphyria (HEP) is caused by a defect in haem biosynthesis through loss of the uroporphyrinogen decarboxylase (*urod*) enzyme (Kappas *et al.* (1995) The Metabolic Basis of Inherited Diseases, pages 2103-2159). The manifestation of this

5 syndrome includes fluorescent and photosensitive red blood cells. One hundred and eighteen embryos were injected with *urod*-MO, and then examined using a rhodamine filter set. Control-MO injected embryos were compared with *urod*-MO injected embryos. All of the injected embryos displayed both fluorescent and photosensitive red blood cells as had been noted in a hypomorphic *urod* mutation (Wang *et al.* (1998) *Nature Genet* 10 20:239-243). Intense auto-fluorescence in the injected embryos indicated accumulation of photosensitive porphyrins in the circulating blood cells. Photosensitivity of blood cells in *urod*-MO injected embryos was evident when embryos were exposed to light.

Exposure to light resulted in depletion of all red blood cells in *urod*-MO injected embryos. The complete phenotypic penetrance of embryos injected with *urod*-MO 15 demonstrates that a MO-based animal model of human disease was generated

Holoprosencephaly (HPE) occurs at high frequency in human embryos (1:250) and in live births (1:16,000) (Wallis *et al.* (1999) *Mol Genet Metab* 68:126-138). In extreme cases, the phenotype is cyclopia. The gene *sonic hedgehog* (*shh*) is thought to play a critical role in the development of this disease in humans (Belloni *et al.* (1996) 20 *Nature Genet* 14:353-356; Roessler *et al.* (1996) *Nature Genet* 14:357-360). Zebrafish *shh* mutations, however, result in no anterior midline signaling defects (Schauerte *et al.* (1998) *Development* 125:2983-2993). A second *shh* orthologue expressed in the anterior midline, *tiggy-winkle hedgehog* (*twhh*) (Ekker *et al.* (1995) *Curr Biol* 5:944-955), could explain this lack of phenotype in a highly conserved vertebrate developmental process.

25 Both *shh* and *twhh* genes were targeted using MOs to test for redundancy and to develop zebrafish as a genetic model for HPE.

Embryos were (1) injected with 18 ng *twhh*-MO and 9 ng of control-MO; (2) injected with 18 ng *shh*-MO and 9 ng of control-MO; (3) co-injected with *shh*-MO and *twhh*-MO, 13.5 ng each; or (4) injected with *shh*-MO and *twhh*-MO (13.5ng each), and 30 100 pg of *twhh* mRNA. Embryos at 3-day old or 10 somite stage were analyzed. Figure 6 is a graph comparing the frequencies of cyclopia, u-somites, and reduced fins in

embryos injected with a control-MO and *twhh*-MO, a control-MO and *shh*-MO, or both *twhh*- and *shh*-MOs.

Embryos injected with *shh*-MO exhibited phenotypes characteristic of a *shh* mutation (Schauerte *et al.* (1998) *Development* 125:2983-2993). These embryos displayed 'u'-shaped somites, lacked the horizontal myoseptum, and had reduced pectoral fins. Embryos injected with *twhh*-MO exhibited phenotypes indistinguishable from controls. These embryos had normal heads, 'v' shaped somites, and normal myoseptum when compared to wildtype embryos. Injection of both *twhh*-MO and *shh*-MO, however, resulted in embryos with synergistic defects in somitic patterning in the trunk, a new phenotype in the forebrain, partial cyclopia, absence of myoseptum, and loss of transcription of the *hedgehog* target gene *patched* (*ptc*) (Concordet *et al.* (1996) *Development* 122:2835-2846).

When 9 ng *twhh*-MO was injected into *shh* deficient embryos (n=52), 100 % penetrance of partial cyclopia was achieved. In contrast, *twhh*-MO failed to cause any cyclopia in sibling embryos (0 %, n=120) (S.Bingham and A.Chandrasekhar, in press). This suggests that zebrafish embryos contain two functionally redundant orthologues of the mammalian *shh* gene with similar roles in anterior midline patterning.

Embryos at the 10 somite stage were examined by whole-mount *in situ* hybridization for *myod*. Results demonstrated that *shh*-MO injected embryos exhibited a weak reduction of adaxial and somatic mesoderm when compared to wildtype embryos. Embryos co-injected with *shh*-MO and *twhh*-MO exhibited an extreme reduction of adaxial mesoderm. This reduction was reversed and adaxial mesoderm was lightly expanded by injection of zebrafish *twhh* mRNA.

These results demonstrate that zebrafish is an effective model for HPE. In addition, these experiments demonstrate the utility of morpholinos for both single and multiple gene knockdowns for the understanding of vertebrate embryonic development and disease.

Example 18 – Sonic hedgehog MO synergy

Embryos were injected, as described in Example 4, with two non-overlapping *shh*-MOs: *shh*-MO #1 and *shh*-MO #2. Sequences of *shh*-MO #1 and *shh*-MO #2 are provided in Example 3. Embryos were analyzed at 3 days of development for phenotypic

changes resulting from loss of sonic hedgehog function (Schauerte *et al.* (1998) *Development* 125: 2983-2993). Embryos that displayed effects in somites as strong as the weakest allele tq252 were scored as demonstrating a positive phenotype. Figure 7 compares the frequencies of embryos that displayed a phenotype associated with sonic hedgehog loss-of-function when injected with one or two shh-MOs. Results shown were obtained from three independent experiments. Twenty or more embryos were scored for each data point. As shown in Figure 7A, the number of embryos having a sonic hedgehog loss-of-function phenotype resulting from morpholino injection was greater when embryos were injected with two shh-MOs than when embryos were injected with a single shh-MO. A comparison of the numbers of embryos having the sonic hedgehog loss-of-function phenotype resulting from injection of one or two shh-MOs demonstrates that the increase was more than additive, i.e., injection with two shh-MOs had a synergistic effect on the number of embryos exhibiting sonic hedgehog loss-of-function phenotype. Furthermore, injection of a half dose of two shh-MOs is much more potent at knocking down *shh* gene expression than a full dose of either MO alone (see Figure 7B).

Example 19 - Efficiency of gene inactivation by morpholinos

Morpholinos were generated against known genes to determine an estimate of success rate. Genes targeted included *shh*, *chordin*, *no tail*, *one-eyed-pinhead (oep)*, *sparse*, *nacre*, *urod*, *bozozok/dharma*, an EF1a-GFP transgene, *pax 2.1*, *bmp1*, *bmp2b*, *bmp7*, *alk8*, *smad5*, *wnt5*, and *wnt11* (see Ekker (2000) *Yeast* 17:302-306). With the exception of *pax 2.1*, all genes targeted resulted in clear specific gene inactivation with the first MO tried, i.e., 16/17 or > 94 % of known genes were inactivated successfully. This rate of successful gene inactivation can be reduced by MO mistargeting or other non-specific effects. For example, an MO can inhibit a second gene resulting in embryos with a combined phenotype. An extreme example is represented by the *bozozok/dharma* MO, in which a second effect (CNS degeneration) is superimposed on the *bozozok* loss of function phenotype (Nasevicius *et al.* (2000) *Nature Genetics* 26:216-220). If these secondary, non-specific effects result in loss of embryonic structures or premature death of the embryo, then the function of the gene under study will not be scorable. The reduction in the rate of successful MO gene inactivation (16/17) by the rate of gene

mistargeting (2/17) is a lower estimate of MO screening efficiency, and yields an initial MO screening rate of 82 % (14/17). A significant fraction of these 'missed' genes can be recovered by the use of a second MO of unrelated sequence. Assuming a similar success rate of approximately 80 % for the remaining 18 % of 'missed' genes, an additional 14 % of genes can be targeted by the second MO, for a combined expected success rate of > 95 % for genes screened using two targeted MOs.

Should the leader sequence in a specific locus be especially prone to polymorphism, the selected gene might not be inactivated in all embryos due to the high specificity of MO targeting *in vivo*. The *one-eyed-pinhead* locus is a potential example of this phenomenon (see Example 14); in one wild-type strain, only ~50% of embryos responded to this MO, in another, none. Other, less direct strain differences also could reduce the effectiveness of MOs. For example, variations in genetic backgrounds could alter the penetrance of a given MO effect due to genetic factors in a second, modulator locus. The characterization and inclusion of common 'wild-type' and other non-isogenic laboratory strains in the sequencing project is suggested to make maximum use of MO technology in zebrafish.

As with many genetic screens, MOs also are limited by functional redundancy, an issue especially relevant to vertebrates. Moreover, the zebrafish genome contains an additional set of incomplete duplicates for an estimated 30% of genes found in mammals (Postlethwait *et al.* (1999) *Methods Cell Biol* 60:149-163; and Oates *et al.* (1999) *Dev Dyn* 215:352-370). This partial genome duplication occasionally results in two orthologues in zebrafish for one in humans. One example is the *sonic hedgehog* locus (Example 17). Comparative expression profiles of likely orthologues, however, demonstrate only a duplication of a subset of expression patterns for these genes. Indeed, no two orthologues have identical expression patterns in zebrafish (Gates *et al.* (1999) *Genome Res* 9:334-347). The use of MOs, however, is highly amenable to rapid tests of redundancy through the simultaneous targeting of genes of related sequence (see Example 17). Multi-gene targeting strategies are thus practical using current morphino technology, with an estimated minimum success rate of $(0.82 \times 0.82) = 67\%$. For genes amenable to this strategy, morpholinos will be extremely effective at identifying and testing molecules with redundant functions *in vivo*.

Example 20 – Morphological effects of VEGF-A-1 morpholino injection at 36 hours

Signaling by members of the *Vascular Endothelial Growth Factor (VEGF)* gene family is implicated in the formation of vasculature during embryogenesis, during wound healing, and for the growth of tumor-induced vasculature (See Carmeliet *et al.* (1996) *Nature* 380:435-9; Carmeliet *et al.* (1997) *Am J Physiol* 273:H2091-104; and Ferrara (1999) *J Mol Med* 77:527-43). Pioneering work in mice with *VEGF-A* demonstrates the extreme dose responsiveness of the mouse embryo to *VEGF-A* signaling during development. Loss of a single copy of the *VEGF-A* gene induces haploinsufficient lethality by day 9.5 pc (Ferrara *et al.* (1996) *Nature* 380:439-42); Carmeliet *et al.* (1996) *Nature* 380:435-9). This biological hurdle to the genetic investigation of *VEGF-A* requirements during later development has resulted in a series of experiments using conditional knockout strategies (Gerber *et al.* (1999) *Development* 126:1149-59; Haigh *et al.* (2000) *Development* 127:1445-53) or dominant negative proteins (Gerber *et al.* (1999) *Development* 126:1149-59). A more recent approach to address this problem used intravenous injection of antisense oligonucleotides in pregnant mice to reveal loss of function requirements of *VEGF-A* function during murine embryogenesis (Driver *et al.* (1999) *Nat Biotechnol* 17:1184-7).

Zebrafish embryos develop externally and have only limited requirements for a functioning circulatory system during early development. For example, embryos with no circulating red blood cells due to porphyria live through the first three days of development (Ransom *et al.* (1996) *Development* 123:311-9), a period that includes all of segmentation and organogenesis in the fish embryo. Multiple mutations in cardiovascular development were isolated in the initial large-scale chemical mutagenesis screens (Stainier *et al.* (1996) *Development* 123:285-92; Chen *et al.* (1996) *Development* 123:293-302; Weinstein *et al.* (1995) *Nat Med* 1:1143-7). Together, the zebrafish has the potential to rapidly assess the biological role of angiogenic factors required for this essential vertebrate process.

Zebrafish *VEGF-A* is expressed during embryogenesis in the anterior nervous system, in mesoderm flanking the prospective heart fields, and in somitic mesoderm that flanks the developing endoderm (Liang *et al.* (1998) *Biochim Biophys* 1397:14-20). MOs

were generated against *VEGF-A* to analyze the requirement of this gene during embryonic development. MOs had been shown to be effective at gene inactivation during the first two days of zebrafish development (see Example 16).

Embryos were injected with 9 ng of VEGF-A-1-MO. The resulting *VEGF-A* morphant embryos developed with no overt abnormal phenotype during the first day of development. At two days of embryogenesis, the *VEGF-A* morphant phenotype consisted of an enlarged pericardium, no circulating red blood cells, a slight reduction in neural tube and overall body size, and little or no functioning vasculature. In a subset of embryos, red blood cell accumulation was observed in the ventral tail. Table 1 summarizes the frequencies of embryos exhibiting loss of vasculature, pericardial edema, blood accumulation in the anterior aorta, and blood accumulation in the tail when injected with the indicated amounts of MO.

Four experiments were performed at each MO dose. Average frequencies of all experiments performed at each MO dose are shown. The standard error is the mean of the differences between the average frequency and the frequencies of individual experiments.

Table 1. Microangiography analysis of embryos injected with VEGF-A-1-MO at 48 hours.

Observed phenotypes (frequency, %)	Injected VEGF-A-1 morpholino dose, ng				
	3	6	9	12	18
Heart and yolk vasculature only	3 ± 2	3 ± 1	21 ± 4	38 ± 13	39 ± 1
No axial or intersegmental vasculature	7 ± 4	2 ± 1	25 ± 3	27 ± 13	29 ± 9
No/reduced intersegmental vasculature	67 ± 5	78 ± 13	51 ± 2	36 ± 20	30 ± 6
Normal vasculature	23 ± 10	17 ± 16	3 ± 1	0 ± 0	2 ± 3
Pericardial edema	15 ± 2	35 ± 10	49 ± 2	55 ± 0	57 ± 2
Blood accumulation in anterior hypochord	0 ± 0	1 ± 1	5 ± 3	3 ± 0	8 ± 2
Blood accumulation in tail	1 ± 1	2 ± 2	16 ± 8	19 ± 0	19 ± 7
Total embryo number	110	120	105	106	101

Example 21 – Microangiography visualization of vasculature defects in VEGF-A-1 morphants

Two separate fluorescent assays were used to assess vascular function. In the first assay, fluorescently-labeled RBCs were generated through inactivation of the *uroporphyrinogen decarboxylase* gene (*urod*; Wang *et al.* (1998) *Nature Genet* 20:239-243) using 9 ng of *urod*-MO. In 36-hour embryos injected with 9 ng of *urod* MO, fluorescing RBCs highlighted the axial vasculature, head vasculature, yolk sac, and heart. In embryos injected with 9 ng of VEGF-A-1-MO, RBCs were localized only to anterior aorta.

In the second assay, the vasculature was directly analyzed by injection with FITC-dextran. Injection of FITC-dextran into the sinus venosa / cardinal vein of an anesthetized 48-hour old embryo results in labeling of the entire vasculature of the zebrafish embryo, including the yolk sac, heart, head, axial, and intersegmental blood vessels (Weinstein *et al.* (1995) *Nat Med* 1:1143-7).

Injection with VEGF-A-1-MO showed that these structures were differentially sensitive to *VEGF-A* signaling. Further, three phenotypic classes were observed when various amounts of VEGF-A-1-MO were injected. In the most severe phenotypic class, i.e., at high dose injections of VEGF-A-1-MO, the only vasculature detectable was in the heart and yolk. Head, axial, and intersegmental blood vessels were not visible. The vasculature either failed to form at all or contained no functioning connections to the heart in these embryos. To distinguish between these possibilities histological analyses were performed on the most severely affected embryos. Neither dorsal aorta nor axial vein could be seen in the injected embryos.

A frequent but less severe phenotypic class of embryos also was observed. These embryos were said to exhibit a moderate VEGF-A-1-MO injection effect. In these embryos, the injected FITC-dextran highlighted yolk sac, heart, and head blood vessels only. No axial or intersegmental vasculature was observed.

The least severe phenotypic classification included embryos exhibiting reduced intersegmental vasculature, but normal heart, yolk, head, and axial blood vessels. Embryos exhibiting no or few intersegmental blood vessels, but normal yolk sac, heart,

head vasculature, and axial blood vessels were said to exhibit a weak VEGF-A-1-MO effect.

The penetrance of these phenotypic classes was dependent on dose (see Table 1). This is consistent with the strong dose-dependence of *VEGF-A* function in mouse embryos (Ferrara *et al.* (1996) *Nature* 380:439-42; Carmeliet *et al.* (1996) *Nature* 380:435-9). Heterozygous mouse *VEGF-A* mutants showed a reduced dorsal aorta detected by histological analysis. Fewer intersegmental blood vessels were detected by a tissue-specific *lacZ* expression. Lack of dorsal aorta was indicated by histological analysis in homozygous mouse *VEGF-A* mutants (Carmeliet *et al.* (1996) *Nature* 380:435-9), suggesting that the most severe zebrafish *VEGF-A* morphant class represents a nearly complete loss of function phenotype. Although mouse *VEGF-A* mutants also displayed heart with under-developed myoblast (Ferrara *et al.* (1996) *Nature* 380:439-42; Haigh *et al.* (2000) *Development* 127:1445-53), the heart in zebrafish *VEGF-A* morphants had essentially a normal appearance with a slightly enlarged atrium and ventricle, possibly due to higher cardiac pressure.

Example 22 – Confirmation of *VEGF-A* MO specificity

Two VEGF-A-MOs, one having a sequence that did not overlap with VEGF-A-1-MO and one containing a four base mismatch, were used to confirm specificity of targeting (see Table 2). Four VEGF-A-D4-MO injection experiments and two VEGF-A-3-MO injection experiments were performed at each MO dose. Table 2 summarizes the average frequencies observed in all experiments performed at each MO dose. The standard error is the mean of the differences between the average frequency and the frequencies of individual experiments.

Injection of embryos with VEGF-A-D4, the mismatched-MO, demonstrated the sequence-specific nature of the noted effects of the VEGF-A-1-MO (see Table 2). To independently test for specificity of targeting to the endogenous *VEGF-A* gene, a second VEGF-A-MO of completely independent sequence (VEGF-A-3) was used. This very potent MO caused the same phenotypic effects on development as the VEGF-A-1-MO, including a dose-dependent reduction of vascular function, pericardial edema, and blood accumulation in the tail (see Table 2). The differential efficacy might be due to different

secondary structures of the MOs or the targeted mRNA regions. Alternatively, the effect might be caused by the higher predicted melting temperature of VEGF-A-3 (48 % G/C) compared to VEGF-A-1 (28 % G/C). Therefore, phenotypes associated with injection of VEGF-A-1-MO resulted from MO-based specific inhibition of translation of *VEGF-A* transcripts.

A number of genes whose mutation results in cardiovascular defects have been observed in chemical mutagenesis screens with zebrafish (Stainier *et al.* (1996) *Development* 123:285-92; Chen *et al.* (1996) *Development* 123:293-302). Although none of the phenotypes associated with these mutations strongly resemble the *VEGF-A* morphant phenotype, the mutant embryos had overlapping phenotypes. Mutations in multiple loci result in embryos with cardiac edema, and a similar accumulation of blood in the ventral tail fin was noted due to disorganized endothelia in the scotch tape (*sco*) mutation (Chen *et al.* (1996) *Development* 123:293-302). Several mutations giving rise to altered circulation were noted (Stainier *et al.* (1996) *Development* 123:285-92); Chen *et al.* (1996) *Development* 123:293-302). These mutations included *gridlock*, a gene that encodes a bHLH protein required only for arterial development (Weinstein *et al.* (1995) *Nat Med* 1:1143-7; Stainier *et al.* (1996) *Development* 123:285-92); Zhong *et al.* (2000) *Science* 287:1820-4). The role of these genes in *VEGF* signaling awaits molecular genetic characterization of the remaining loci.

Table 2. Microangiography analysis of embryos injected with VEGF-A-D4 and VEGF-A-3-MO at 48 hours

VEGF-A-D4 morpholino	Injected dose, ng				
	3	6	9	12	18
Heart and yolk vasculature only	1 ± 1	0 ± 0	2 ± 3	3 ± 0	3 ± 0
No axial or intersegmental vasculature	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0
No/reduced intersegmental vasculature	7 ± 0	6 ± 3	5 ± 2	22 ± 1	14 ± 3
Normal vasculature	92 ± 1	94 ± 3	93 ± 3	75 ± 2	84 ± 3
Total embryo number	163	116	119	76	73
VEGF-A-3 morpholino	0.5	1.5	3		
Heart and yolk vasculature only	0 ± 0	13 ± 13	27 ± 11		
No axial or intersegmental vasculature	0 ± 0	24 ± 24	40 ± 13		
No/reduced intersegmental vasculature	18.8	37 ± 11	24 ± 14		
Normal vasculature	81.2	26 ± 26	10 ± 10		
Total embryo number	32	71	69		

Example 23 – Comparative expression of *fli-1* and *flk-1* in 26 hour-wild type and VEGF-A-1 morpholino injected zebrafish embryos

Expressions of two endodermal vascular markers, *fli-1* and *flk-1*, in VEGF-A morphant embryos were analyzed. The transcription factor *fli-1* is a very early marker of vascular cell fate specification (Thompson *et al.* (1998) *Dev Biol* 197:248-69; Brown *et al.* (2000) *Mech Dev* 92:237-52). In wild-type 26-hour embryos, *fli-1* was expressed in the forming dorsal aorta and axial vein and in the intersegmental vasculature in overlying somites. In embryos that failed to complete vascular development, only a subset of the vascular expression patterns of *fli-1* was altered. No detectable intersegmental expression of *fli-1* was observed. This coincided with the exquisite intersegmental vascular endoderm sensitivity to VEGF signaling (Table 1). The cells either were not properly specified or failed to migrate during formation of the intersegmental vessels.

The distinct responsiveness of the expression of the endothelial marker *fli-1* in intersegmental vessels to *VEGF-A* signaling demonstrates a dual role for *VEGF* during vascular development. First, *VEGF-A* is required for proper axial vessel formation but not for initial axial vessel patterning. Second, *VEGF-A* is required for intersegmental vessel cell specification or migration, and presumably, for subsequent vascular formation.

Similar results were obtained upon analysis of expression of the tyrosine kinase *VEGF* receptor *flk-1*. Distribution of *flk-1* transcripts was very similar to that of *fli-1* in the trunk and tail of wild-type embryos. In *VEGF-A* morphant embryos generated by injection with 9 ng VEGF-A-1, intersegmental but not axial expression was absent. A significant reduction in *flk-1* gene expression was noted in mouse embryos with no *VEGF-A* activity (Carmeliet *et al.* (1996) *Nature* 380:435-9). A less extreme lack of *flk-1* expressing cells in the intersegmental vasculature also was observed in mouse with the partial and conditional *VEGF-A* knockout (Haigh *et al.* (2000) *Development* 127:1445-53).

Zebrafish embryos injected with 18 ng of VEGF-A-1-MO displayed the same specific loss of expression only in the intersegmental regions for both *fli-1* and *flk-1*. The lack of a requirement for *VEGF* signaling for *flk-1* expression is consistent with previous observations of paracrine modes of *VEGF* signaling (reviewed in Ferrara, 1999). The expression of the *VEGF* receptor *flk-1* is, however, *VEGF*-dependent during intersegmental vascularization. This latter observation suggests a possible autoregulatory loop, functioning during vasculogenesis of the intersegmental vessels. The strong conservation of *VEGF* function from fish to mammals implicates this as a fundamental vertebrate biological pathway.

These experiments demonstrate a fundamental distinction between *VEGF-A* requirements for axial and intersegmental vascular structure specification. More specifically, *VEGF-A* is not required for the initial establishment of axial vasculature patterning, whereas all development of intersegmental vasculature is dependent on *VEGF-A* signaling. The absence of axial and intersegmental vasculature in *VEGF-A* morphant embryos indicates that *VEGF-A* has a role beyond establishing *flk-1* and *fli-1* expression in blood vessel formation.

Example 24 – VEGF-MO synergy

Embryos were injected, as described in Example 4, with two VEGF-MOs: VEGF-A-1-MO and VEGF-A-3-MO. Sequences for the VEGF-A-1-MO and VEGF-A-3-MO are provided in Example 3. Embryos at 2 days of development were analyzed using microangiography, as described in Example 21. Embryos that displayed defects in intersegmental vasculature only were scored as displaying a weak VEGF-MO phenotype, whereas embryos that displayed defects in both intersegmental and axial vasculature were scored as a strong VEGF-MO phenotype. Results, depicted in Figure 8, demonstrate that the number of embryos having a weak or strong VEGF-MO phenotype resulting from morpholino injection was greater when embryos were injected with two VEGF-MOs than when embryos were injected with a single VEGF-MO. A comparison of the numbers of embryos having the weak or strong VEGF-MO phenotype resulting from injection of one or two VEGF-MOs demonstrates that the increase was more than additive, i.e., injection with two MOs had a synergistic effect on the numbers of embryos exhibiting weak or strong VEGF-MO phenotypes.

Example 25 - Zebrafish frizzled-2 targeting analyses

Embryos were injected, as described in Example 4, with two zfh2-MOs: zfh2-MO-ATG and zfh2-MO-UTR. Sequences for zfh2-MO-ATG and zfh2-MO-UTR are provided in Example 3. Figure 9 is a bar graph showing the percentages of embryos affected by injection with either one of the two zfh2-MOs or both zfh2-MOs. The zfh2-associated developmental defects are undulating notochords and wider than normal posterior-concentrated somites during embryogenesis. Embryos injected with either a single zfh2-MO or two zfh2-MOs were examined for these morphologically-visible defects. Both zfh2-MOs were capable of eliciting similar undulated notochord and somite defects when injected individually into an embryo. When both of the zfh2-MOs were injected into the same embryo, defects in notochord and somite developments were synergistic.

In addition, development of the zebrafish pancreas was examined using pancreas-specific markers such as Fspndin and islet-1. Fspndin and islet-1 are expressed by a subset of cells in the zebrafish pancreas, and the absence of expression of Fspndin or

islet-1 indicates that pancreas development is defective. When Fspodin and islet-1 expressions were examined, reduced expression or a complete lack of expression was found in morpholino-injected embryos.

5 Example 26 – Vertebrate Tsg functions to augment Chordin inhibitory activity

To examine the function of *tsg* in vertebrates, the function of the *ztsg1* gene in zebrafish was analyzed using a *ztsg1*-MO. The *ztsg1* gene is the appropriate counterpart to the early embryonic *Drosophila tsg* since *ztsg1* is expressed ubiquitously in early zebrafish embryos, while *ztsg2* is only expressed at later stages.

10 MOs were used to reduce the function of the endogenous *ztsg1*. To visualize the vasculature, 9 ng of UroD-MO was injected into embryos. *In situ* hybridizations were performed for the following markers at the indicated developmental stages: *MyoD* (8 somite stage), *Krox20* (8 somite), *GATA2* (22 somite) and *BMP-4* (3 somite stage).
15 Injection of 12 ng of a *ztsg1* morpholino (*ztsg*-MO) resulted in 50 % of the injected embryos giving rise to zebrafish with phenotypes characteristic of expanded BMP signaling (Hammerschmidt *et al.* (1996) *Develop* 123:95-102; Miller-Bertoglio *et al.* (1999) *Dev Biol* 214:72-86). Embryos developed expansion of the ventral fin region that corresponded to ectopic blood islands, a tissue derived from ventral mesoderm. Injected embryos also showed an expansion of *GATA2* at the 22 somite stage of development (48
20 %, n = 21), loss of paraxial mesoderm (visualized with the marker *MyoD*) at the 8 somite stage (38 %, n = 33), and a mild reduction of anterior ectodermal tissues (detected by staining for *Krox-20*) at the 8 somite stage (49 %, n = 39). Caudal expression of *BMP4* also was expanded in these embryos at the 3 somite stage (48 %, n = 25), while the anterior ectodermal marker *otx-2* was reduced. Treated embryos also exhibited an
25 expansion in apoptotic cells ventral to the yolk extension similar to *dino* and *mercedes* mutants (Hammerschmidt *et al.* (1996) *Develop* 123:95-102; Fisher *et al.* (1997) *Develop* 124:1301-11). Overall, this phenotype is very similar to that of *ogon/mercedes* mutants (Hammerschmidt *et al.* (1996) *Develop* 123:95-102; Miller-Bertoglio *et al.* (1999) *Dev Biol* 214:72-86) and moderate *chordin* loss-of-function mutants, and represents a modest
30 ventralized phenotype (Nasevicius *et al.* (2000) *Nat Gen* 26:216-220; Hammerschmidt *et al.* (1996) *Develop* 123:95-102).

Injection of *ztsg1* mRNA resulted in phenotypes diagnostic of reduced BMP signaling (Mullins *et al.* (1996) *Develop* 123:81-93; Kishimoto *et al.* (1997) *Develop* 124:4457-66; Dick *et al.* (2000) *Develop* 127:343-54). Injection of 75 pg of *ztsg1* mRNA resulted in 56 % of the surviving animals (164 injected, 108 alive) exhibiting reduced axial length with loss of ventral fin. This is a phenocopy of the C3-C4 class of dorsalized mutant embryos observed with the *snailhouse* (BMP-7 homologue) and *piggytail* mutations (Mullins *et al.* (1996) *Develop* 123:81-93; Dick *et al.* (2000) *Develop* 127:343-54). Molecular analysis revealed a similar expansion of *MyoD* (50 %, n = 8) and *Krox20* (70 %, n = 10) at the 8 somite stage. Furthermore, the dorsalizing effect of *ztsg1* mRNA partially reversed the ventralizing effect of the *ztsg1*-MO (9 ng *tsg1*-MO caused 47 ± 2 % ventralized embryos (n = 376); 9 ng *ztsg1*-MO plus 30 pg *ztsg1* mRNA resulted in 19 ± 8 % ventralized embryos (n = 270)) indicating that loss of *ztsg1* was responsible for the phenotype. Therefore, loss of *ztsg1* led to embryos with a ventralized phenotype, while ectopic expression of *ztsg1* led to a dorsalized embryonic phenotype.

Example 27 - Enhancement of the *ztsg1* loss-of-function phenotype by sub-inhibitory loss of the Chordin gene

Drosophila data suggest that one role of Tsg is to potentiate the inhibition of BMP signaling in conjunction with Sog/Chordin. To determine if the same is true for vertebrates, sub-inhibitory levels of chordin-MO and *ztsg1*-MO were injected into wild type embryos and the effect on ectopic blood island development was scored. Embryos were injected with either a low dose of *ztsg1*-MO, chordin-MO, or both *ztsg1*-MO and chordin-MO, and the resulting embryos were examined for blood island expansion. Results, depicted in Figure 10, demonstrate that *ztsg1*-MO and chordin-MO synergistically enhanced blood island expansion. Co-injection of sub-inhibitory levels of MOs directed against both Tsg and Chordin synergistically enhances the penetrance of the ventralized phenotype. Therefore, both gene products cooperatively inhibited BMP signaling. The finding that Tsg and Chordin cooperate to inhibit BMP-2 signalling was confirmed by results of biochemical experiments performed in *Drosophila* as well as in *Xenopus* (See Ross *et al.* (2001) *Nature* 410:479-83.)

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate
5 and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000